{
"instance": {
"synh-10q_20210331.htm": {
"axisCustom": 0,
"axisStandard": 32,
"contextCount": 199,
"dts": {
"calculationLink": {
"local": [
"synh-20210331_cal.xml"
]
},
"definitionLink": {
"local": [
"synh-20210331_def.xml"
],
"remote": [
"http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
"http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
]
},
"inline": {
"local": [
"synh-10q_20210331.htm"
]
},
"labelLink": {
"local": [
"synh-20210331_lab.xml"
],
"remote": [
"https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
]
},
"presentationLink": {
"local": [
"synh-20210331_pre.xml"
]
},
"referenceLink": {
"remote": [
"https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
]
},
"schema": {
"local": [
"synh-20210331.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
"http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
"https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
"https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
"http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
"https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
"http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
"https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
"http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
"http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
"https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
"http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
]
}
},
"elementCount": 504,
"entityCount": 1,
"hidden": {
"http://fasb.org/us-gaap/2020-01-31": 6,
"http://xbrl.sec.gov/dei/2020-01-31": 5,
"total": 11
},
"keyCustom": 24,
"keyStandard": 315,
"memberCustom": 26,
"memberStandard": 50,
"nsprefix": "synh",
"nsuri": "http://www.syneoshealth.com/20210331",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"p",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "100000 - Document - Cover Page",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage",
"shortName": "Cover Page",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100090 - Disclosure - Financial Statement Details",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetails",
"shortName": "Financial Statement Details",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessCombinationDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100100 - Disclosure - Business Combinations",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinations",
"shortName": "Business Combinations",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessCombinationDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100110 - Disclosure - Long-Term Debt Obligations",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligations",
"shortName": "Long-Term Debt Obligations",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100120 - Disclosure - Derivatives",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivatives",
"shortName": "Derivatives",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100130 - Disclosure - Fair Value Measurements",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurements",
"shortName": "Fair Value Measurements",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100140 - Disclosure - Restructuring and Other Costs",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCosts",
"shortName": "Restructuring and Other Costs",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100150 - Disclosure - Shareholders' Equity",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquity",
"shortName": "Shareholders' Equity",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100160 - Disclosure - Earnings Per Share",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShare",
"shortName": "Earnings Per Share",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100170 - Disclosure - Income Taxes",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureIncomeTaxes",
"shortName": "Income Taxes",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100180 - Disclosure - Revenue from Contracts with Customers",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRevenueFromContractsWithCustomers",
"shortName": "Revenue from Contracts with Customers",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100010 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
"shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"lang": null,
"name": "us-gaap:Depreciation",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SegmentReportingDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100190 - Disclosure - Segment Information",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformation",
"shortName": "Segment Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SegmentReportingDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "synh:GeographicInformationTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100200 - Disclosure - Operations by Geographic Location",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocation",
"shortName": "Operations by Geographic Location",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "synh:GeographicInformationTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100210 - Disclosure - Concentration of Credit Risk",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureConcentrationOfCreditRisk",
"shortName": "Concentration of Credit Risk",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100220 - Disclosure - Related-Party Transactions",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactions",
"shortName": "Related-Party Transactions",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R24": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100230 - Disclosure - Commitments and Contingencies",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies",
"shortName": "Commitments and Contingencies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R25": {
"firstAnchor": {
"ancestors": [
"us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100240 - Disclosure - Basis of Presentation and Changes in Significant Accounting Policies (Policies)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBasisOfPresentationAndChangesInSignificantAccountingPoliciesPolicies",
"shortName": "Basis of Presentation and Changes in Significant Accounting Policies (Policies)",
"subGroupType": "policies",
"uniqueAnchor": {
"ancestors": [
"us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "synh:ScheduleOfCashPoolPositionTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100250 - Disclosure - Financial Statement Details (Tables)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables",
"shortName": "Financial Statement Details (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "synh:ScheduleOfCashPoolPositionTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R27": {
"firstAnchor": {
"ancestors": [
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100260 - Disclosure - Long-Term Debt Obligations (Tables)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsTables",
"shortName": "Long-Term Debt Obligations (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R28": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100270 - Disclosure - Derivatives (Tables)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesTables",
"shortName": "Derivatives (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R29": {
"firstAnchor": {
"ancestors": [
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100280 - Disclosure - Fair Value Measurements (Tables)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables",
"shortName": "Fair Value Measurements (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100020 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited",
"shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"lang": null,
"name": "synh:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent1",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R30": {
"firstAnchor": {
"ancestors": [
"us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100290 - Disclosure - Restructuring and Other Costs (Tables)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsTables",
"shortName": "Restructuring and Other Costs (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R31": {
"firstAnchor": {
"ancestors": [
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100300 - Disclosure - Shareholders' Equity (Tables)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityTables",
"shortName": "Shareholders' Equity (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R32": {
"firstAnchor": {
"ancestors": [
"us-gaap:EarningsPerShareTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100310 - Disclosure - Earnings Per Share (Tables)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareTables",
"shortName": "Earnings Per Share (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:EarningsPerShareTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R33": {
"firstAnchor": {
"ancestors": [
"us-gaap:SegmentReportingDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100320 - Disclosure - Segment Information (Tables)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationTables",
"shortName": "Segment Information (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:SegmentReportingDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R34": {
"firstAnchor": {
"ancestors": [
"synh:GeographicInformationTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100330 - Disclosure - Operations by Geographic Location (Tables)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTables",
"shortName": "Operations by Geographic Location (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"synh:GeographicInformationTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R35": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:NumberOfReportableSegments",
"reportCount": 1,
"unitRef": "U_synhSegment",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100340 - Disclosure - Basis of Presentation and Changes in Significant Accounting Policies - Narrative (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBasisOfPresentationAndChangesInSignificantAccountingPoliciesNarrativeDetails",
"shortName": "Basis of Presentation and Changes in Significant Accounting Policies - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R36": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"synh:ScheduleOfCashPoolPositionTableTextBlock",
"us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "synh:CashandCashEquivalentsCashPoolingAgreementGrossCashPosition",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100350 - Disclosure - Financial Statement Details - Schedule Of Cash Pool Position (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfCashPoolPositionDetails",
"shortName": "Financial Statement Details - Schedule Of Cash Pool Position (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"synh:ScheduleOfCashPoolPositionTableTextBlock",
"us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "synh:CashandCashEquivalentsCashPoolingAgreementGrossCashPosition",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R37": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
"us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AccountsReceivableGrossCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100360 - Disclosure - Financial Statement Details - Accounts Receivable and Unbilled Services, net (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccountsReceivableAndUnbilledServicesNetDetails",
"shortName": "Financial Statement Details - Accounts Receivable and Unbilled Services, net (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
"us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AccountsReceivableGrossCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R38": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-5",
"first": true,
"lang": null,
"name": "synh:TradeReceivablesSold",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100370 - Disclosure - Financial Statement Details - Narrative (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsNarrativeDetails",
"shortName": "Financial Statement Details - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-5",
"first": true,
"lang": null,
"name": "synh:TradeReceivablesSold",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R39": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20201231",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:Goodwill",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100380 - Disclosure - Financial Statement Details - Schedule of Goodwill (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfGoodwillDetails",
"shortName": "Financial Statement Details - Schedule of Goodwill (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfGoodwillTextBlock",
"us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"lang": null,
"name": "us-gaap:GoodwillPurchaseAccountingAdjustments",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnauditedParenthetical",
"shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R40": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20201231",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:StockholdersEquity",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100390 - Disclosure - Financial Statement Details - Accumulated Other Comprehensive Loss, Net of Taxes (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccumulatedOtherComprehensiveLossNetOfTaxesDetails",
"shortName": "Financial Statement Details - Accumulated Other Comprehensive Loss, Net of Taxes (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedTranslationAdjustmentMember_20201231",
"decimals": "-3",
"lang": null,
"name": "us-gaap:StockholdersEquity",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R41": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100400 - Disclosure - Financial Statement Details - Tax Effects Allocated to Each Component of Other Comprehensive (Loss) Income (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTaxEffectsAllocatedToEachComponentOfOtherComprehensiveLossIncomeDetails",
"shortName": "Financial Statement Details - Tax Effects Allocated to Each Component of Other Comprehensive (Loss) Income (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"lang": null,
"name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R42": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ForeignCurrencyTransactionGainLossRealized",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100410 - Disclosure - Financial Statement Details - Other Income, Net (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherIncomeNetDetails",
"shortName": "Financial Statement Details - Other Income, Net (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"lang": null,
"name": "us-gaap:ForeignCurrencyTransactionGainLossUnrealized",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R43": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:BusinessCombinationDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20201208_20201209",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessAcquisitionNameOfAcquiredEntity",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100420 - Disclosure - Business Combinations - Narrative (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinationsNarrativeDetails",
"shortName": "Business Combinations - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:BusinessCombinationDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20201208_20201209",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessAcquisitionNameOfAcquiredEntity",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R44": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfDebtInstrumentsTextBlock",
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100430 - Disclosure - Long-Term Debt Obligations - Schedule of Debt Obligations (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails",
"shortName": "Long-Term Debt Obligations - Schedule of Debt Obligations (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfDebtInstrumentsTextBlock",
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_20210331",
"decimals": "-3",
"lang": null,
"name": "us-gaap:DebtInstrumentCarryingAmount",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R45": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:RepaymentsOfLongTermDebt",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100440 - Disclosure - Long-Term Debt Obligations - Narrative (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails",
"shortName": "Long-Term Debt Obligations - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_20210331",
"decimals": "INF",
"lang": null,
"name": "us-gaap:LineOfCredit",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R46": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:LongTermDebt",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100450 - Disclosure - Long-Term Debt Obligations - Accounts Receivable Financing Agreement (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails",
"shortName": "Long-Term Debt Obligations - Accounts Receivable Financing Agreement (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapDebtInstrumentAxis_synhAccountsReceivableFinancingAgreementDueOctober2022Member_20210126_20210128",
"decimals": "-5",
"lang": null,
"name": "us-gaap:LineOfCreditFacilityDecreaseForgiveness1",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R47": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100460 - Disclosure - Long-Term Debt Obligations - Contractual Maturities of Debt Obligations (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails",
"shortName": "Long-Term Debt Obligations - Contractual Maturities of Debt Obligations (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R48": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ForeignCurrencyTransactionGainLossRealized",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100470 - Disclosure - Derivatives - Narrative (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesNarrativeDetails",
"shortName": "Derivatives - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapDerivativeInstrumentRiskAxis_synhInterestRateSwapExpiringMarch312023Member_20210331",
"decimals": "-5",
"lang": null,
"name": "us-gaap:DerivativeNotionalAmount",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R49": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapDerivativeInstrumentRiskAxis_us-gaapInterestRateSwapMember_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaapCashFlowHedgingMember_us-gaapHedgingDesignationAxis_us-gaapDesignatedAsHedgingInstrumentMember_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DerivativeLiabilities",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100480 - Disclosure - Derivatives - Interest Rate Swaps Designated as Hedging Instruments on Consolidated Balance Sheets (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails",
"shortName": "Derivatives - Interest Rate Swaps Designated as Hedging Instruments on Consolidated Balance Sheets (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapDerivativeInstrumentRiskAxis_us-gaapInterestRateSwapMember_us-gaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaapCashFlowHedgingMember_us-gaapHedgingDesignationAxis_us-gaapDesignatedAsHedgingInstrumentMember_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DerivativeLiabilities",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100040 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
"shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-3",
"lang": null,
"name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R50": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:TradingSecurities",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100490 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"shortName": "Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:TradingSecurities",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R51": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:ContractualObligation",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100500 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Parenthetical) (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetails",
"shortName": "Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Parenthetical) (Details)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:ContractualObligation",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R52": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20201231",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100510 - Disclosure - Fair Value Measurements - Reconciliation of Changes in the Carrying Amount of Contingent Consideration (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfChangesInCarryingAmountOfContingentConsiderationDetails",
"shortName": "Fair Value Measurements - Reconciliation of Changes in the Carrying Amount of Contingent Consideration (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20201231",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R53": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100520 - Disclosure - Fair Value Measurements - Narrative (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsNarrativeDetails",
"shortName": "Fair Value Measurements - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R54": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapDebtInstrumentAxis_synhA2017CreditAgreementAmendmentNo2TermLoanATrancheOneDueMarch2024Member_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DebtLongtermAndShorttermCombinedAmount",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100530 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails",
"shortName": "Fair Value Measurements - Schedule of Estimated Fair Value (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapDebtInstrumentAxis_synhA2017CreditAgreementAmendmentNo2TermLoanATrancheOneDueMarch2024Member_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DebtLongtermAndShorttermCombinedAmount",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R55": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
"us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100540 - Disclosure - Restructuring and Other Costs - Schedule of Restructuring and Related Costs (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsScheduleOfRestructuringAndRelatedCostsDetails",
"shortName": "Restructuring and Other Costs - Schedule of Restructuring and Related Costs (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
"us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R56": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapBusinessRestructuringReservesMember_20201231",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ValuationAllowancesAndReservesBalance",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100550 - Disclosure - Restructuring and Other Costs - Liabilities Associated with Restructuring and Other Costs (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsLiabilitiesAssociatedWithRestructuringAndOtherCostsDetails",
"shortName": "Restructuring and Other Costs - Liabilities Associated with Restructuring and Other Costs (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapBusinessRestructuringReservesMember_20201231",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ValuationAllowancesAndReservesBalance",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R57": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:SharesOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100560 - Disclosure - Shareholders' Equity - Shares of Common Stock Outstanding (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquitySharesOfCommonStockOutstandingDetails",
"shortName": "Shareholders' Equity - Shares of Common Stock Outstanding (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:SharesOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
}
},
"R58": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:CommonStockParOrStatedValuePerShare",
"reportCount": 1,
"unitRef": "U_iso4217USD_xbrlishares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100570 - Disclosure - Shareholders' Equity - Narrative (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityNarrativeDetails",
"shortName": "Shareholders' Equity - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20201117",
"decimals": "-5",
"lang": null,
"name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R59": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfRepurchaseAgreements",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20210201_20210228",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:StockRepurchasedDuringPeriodShares",
"reportCount": 1,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100580 - Disclosure - Shareholders' Equity - Repurchase Activity (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityRepurchaseActivityDetails",
"shortName": "Shareholders' Equity - Repurchase Activity (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfRepurchaseAgreements",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20210201_20210228",
"decimals": "2",
"lang": null,
"name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD_xbrlishares",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:PreferredStockParOrStatedValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD_xbrlishares",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100050 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
"shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:PreferredStockParOrStatedValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD_xbrlishares",
"xsiNil": "false"
}
},
"R60": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100590 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
"shortName": "Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"us-gaap:EarningsPerShareTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"lang": null,
"name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
}
},
"R61": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:EarningsPerShareTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100600 - Disclosure - Earnings Per Share - Narrative (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareNarrativeDetails",
"shortName": "Earnings Per Share - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:EarningsPerShareTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
}
},
"R62": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:IncomeTaxExpenseBenefit",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100610 - Disclosure - Income Taxes - Narrative (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails",
"shortName": "Income Taxes - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-5",
"lang": null,
"name": "synh:IncomeTaxesDiscreteTaxExpenseBenefits",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R63": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-7",
"first": true,
"lang": null,
"name": "us-gaap:RevenueRemainingPerformanceObligation",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100620 - Disclosure - Revenue from Contracts with Customers - Narrative (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersNarrativeDetails",
"shortName": "Revenue from Contracts with Customers - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-7",
"first": true,
"lang": null,
"name": "us-gaap:RevenueRemainingPerformanceObligation",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R64": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:NumberOfReportableSegments",
"reportCount": 1,
"unitRef": "U_synhSegment",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100630 - Disclosure - Segment Information (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails",
"shortName": "Segment Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_20210101_20210331",
"decimals": "-3",
"lang": null,
"name": "us-gaap:CostOfGoodsAndServicesSold",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R65": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100640 - Disclosure - Operations by Geographic Location - Total Revenue by Geographic Area (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails",
"shortName": "Operations by Geographic Location - Total Revenue by Geographic Area (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
"synh:GeographicInformationTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_srtStatementGeographicalAxis_srtNorthAmericaMember_20210101_20210331",
"decimals": "-3",
"lang": null,
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R66": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:PropertyPlantAndEquipmentNet",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100650 - Disclosure - Operations by Geographic Location - Long-Lived Assets by Geographic Area (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationLongLivedAssetsByGeographicAreaDetails",
"shortName": "Operations by Geographic Location - Long-Lived Assets by Geographic Area (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_srtStatementGeographicalAxis_srtNorthAmericaMember_20210331",
"decimals": "-3",
"lang": null,
"name": "us-gaap:PropertyPlantAndEquipmentNet",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R67": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:ConcentrationRiskDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20210331",
"decimals": "2",
"first": true,
"lang": null,
"name": "us-gaap:ConcentrationRiskPercentage1",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlipure",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100660 - Disclosure - Concentration of Credit Risk - Narrative (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureConcentrationOfCreditRiskNarrativeDetails",
"shortName": "Concentration of Credit Risk - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:ConcentrationRiskDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20210331",
"decimals": "2",
"first": true,
"lang": null,
"name": "us-gaap:ConcentrationRiskPercentage1",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlipure",
"xsiNil": "false"
}
},
"R68": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:RevenueFromRelatedParties",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100670 - Disclosure - Related-Party Transactions - Narrative (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactionsNarrativeDetails",
"shortName": "Related-Party Transactions - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:RevenueFromRelatedParties",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R69": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100680 - Disclosure - Commitments and Contingencies - Narrative (Details)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
"shortName": "Commitments and Contingencies - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_us-gaapBusinessAcquisitionAxis_synhInVentivMergerMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331",
"decimals": "-5",
"lang": null,
"name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
"shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": "-3",
"lang": null,
"name": "us-gaap:DepreciationDepletionAndAmortization",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20191231",
"decimals": "-3",
"first": true,
"lang": null,
"name": "synh:StockholdersEquityAttributableToParentAdjustedBalance",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100070 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited)",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited",
"shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20191231",
"decimals": "-3",
"first": true,
"lang": null,
"name": "synh:StockholdersEquityAttributableToParentAdjustedBalance",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100080 - Disclosure - Basis of Presentation and Changes in Significant Accounting Policies",
"role": "http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBasisOfPresentationAndChangesInSignificantAccountingPolicies",
"shortName": "Basis of Presentation and Changes in Significant Accounting Policies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "synh-10q_20210331.htm",
"contextRef": "C_0001610950_20210101_20210331",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 77,
"tag": {
"country_US": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "UNITED STATES",
"terseLabel": "United States"
}
}
},
"localname": "US",
"nsuri": "http://xbrl.sec.gov/country/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationLongLivedAssetsByGeographicAreaDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "domainItemType"
},
"dei_AmendmentFlag": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag",
"terseLabel": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code",
"terseLabel": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Cover page.",
"label": "Cover [Abstract]"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"xbrltype": "stringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date",
"terseLabel": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus",
"terseLabel": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus",
"terseLabel": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date",
"terseLabel": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r531"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report",
"terseLabel": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r532"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report",
"terseLabel": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type",
"terseLabel": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address Address Line1",
"terseLabel": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address City Or Town",
"terseLabel": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address Postal Zip Code",
"terseLabel": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address State Or Province",
"terseLabel": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r533"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock Shares Outstanding",
"terseLabel": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status",
"terseLabel": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r533"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company",
"terseLabel": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number",
"terseLabel": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r533"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category",
"terseLabel": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation State Country Code",
"terseLabel": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r534"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current",
"terseLabel": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r533"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name",
"terseLabel": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r533"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company",
"terseLabel": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r533"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business",
"terseLabel": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r533"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number",
"terseLabel": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "employerIdItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number",
"terseLabel": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r529"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Security12b Title",
"terseLabel": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r530"
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name",
"terseLabel": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_TradingSymbol": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol",
"terseLabel": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DocumentCoverPage"
],
"xbrltype": "tradingSymbolItemType"
},
"srt_AsiaPacificMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Asia Pacific [Member]",
"terseLabel": "Asia-Pacific"
}
}
},
"localname": "AsiaPacificMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationLongLivedAssetsByGeographicAreaDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "domainItemType"
},
"srt_ConsolidatedEntitiesAxis": {
"auth_ref": [
"r362",
"r363",
"r366",
"r367",
"r528"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidated Entities [Axis]",
"terseLabel": "Consolidated Entities"
}
}
},
"localname": "ConsolidatedEntitiesAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails"
],
"xbrltype": "stringItemType"
},
"srt_ConsolidatedEntitiesDomain": {
"auth_ref": [
"r362",
"r363",
"r366",
"r367"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidated Entities [Domain]",
"terseLabel": "Consolidated Entities"
}
}
},
"localname": "ConsolidatedEntitiesDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails"
],
"xbrltype": "domainItemType"
},
"srt_ConsolidationItemsAxis": {
"auth_ref": [
"r151",
"r164",
"r165",
"r166",
"r167",
"r169",
"r171",
"r175"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidation Items [Axis]",
"terseLabel": "Consolidation Items"
}
}
},
"localname": "ConsolidationItemsAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "stringItemType"
},
"srt_ConsolidationItemsDomain": {
"auth_ref": [
"r151",
"r164",
"r165",
"r166",
"r167",
"r169",
"r171",
"r175"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidation Items [Domain]",
"terseLabel": "Consolidation Items"
}
}
},
"localname": "ConsolidationItemsDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
"auth_ref": [
"r104",
"r111",
"r195",
"r311",
"r312",
"r313",
"r334",
"r335"
],
"lang": {
"en-us": {
"role": {
"label": "Cumulative Effect Period Of Adoption Adjustment [Member]",
"terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
}
}
},
"localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "domainItemType"
},
"srt_CumulativeEffectPeriodOfAdoptionAxis": {
"auth_ref": [
"r104",
"r111",
"r195",
"r311",
"r312",
"r313",
"r334",
"r335"
],
"lang": {
"en-us": {
"role": {
"label": "Cumulative Effect Period Of Adoption [Axis]",
"terseLabel": "Cumulative Effect, Period of Adoption"
}
}
},
"localname": "CumulativeEffectPeriodOfAdoptionAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "stringItemType"
},
"srt_CumulativeEffectPeriodOfAdoptionDomain": {
"auth_ref": [
"r104",
"r111",
"r195",
"r311",
"r312",
"r313",
"r334",
"r335"
],
"lang": {
"en-us": {
"role": {
"label": "Cumulative Effect Period Of Adoption [Domain]",
"terseLabel": "Cumulative Effect, Period of Adoption"
}
}
},
"localname": "CumulativeEffectPeriodOfAdoptionDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "domainItemType"
},
"srt_DirectorMember": {
"auth_ref": [
"r186"
],
"lang": {
"en-us": {
"role": {
"label": "Director [Member]",
"verboseLabel": "Board of Directors"
}
}
},
"localname": "DirectorMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_LatinAmericaMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Latin America [Member]",
"terseLabel": "Latin America"
}
}
},
"localname": "LatinAmericaMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationLongLivedAssetsByGeographicAreaDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "domainItemType"
},
"srt_LitigationCaseAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Litigation Case [Axis]",
"terseLabel": "Litigation Case"
}
}
},
"localname": "LitigationCaseAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"srt_LitigationCaseTypeDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Litigation Case Type [Domain]",
"terseLabel": "Litigation Case"
}
}
},
"localname": "LitigationCaseTypeDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_MaximumMember": {
"auth_ref": [
"r299",
"r302",
"r449",
"r450",
"r451",
"r452",
"r453",
"r454",
"r455",
"r486",
"r488"
],
"lang": {
"en-us": {
"role": {
"label": "Maximum [Member]",
"terseLabel": "Maximum [Member]"
}
}
},
"localname": "MaximumMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_MinimumMember": {
"auth_ref": [
"r299",
"r302",
"r449",
"r450",
"r451",
"r452",
"r453",
"r454",
"r455",
"r486",
"r488"
],
"lang": {
"en-us": {
"role": {
"label": "Minimum [Member]",
"terseLabel": "Minimum [Member]"
}
}
},
"localname": "MinimumMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_NorthAmericaMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "North America [Member]",
"terseLabel": "North America"
}
}
},
"localname": "NorthAmericaMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationLongLivedAssetsByGeographicAreaDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "domainItemType"
},
"srt_OwnershipAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Ownership [Axis]",
"terseLabel": "Ownership"
}
}
},
"localname": "OwnershipAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetails"
],
"xbrltype": "stringItemType"
},
"srt_OwnershipDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Ownership [Domain]",
"terseLabel": "Ownership"
}
}
},
"localname": "OwnershipDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetails"
],
"xbrltype": "domainItemType"
},
"srt_PartnershipInterestMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Partnership Interest [Member]",
"terseLabel": "Partnership Interest"
}
}
},
"localname": "PartnershipInterestMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"srt_RangeAxis": {
"auth_ref": [
"r288",
"r299",
"r302",
"r449",
"r450",
"r451",
"r452",
"r453",
"r454",
"r455",
"r486",
"r488"
],
"lang": {
"en-us": {
"role": {
"label": "Range [Axis]",
"terseLabel": "Statistical Measurement"
}
}
},
"localname": "RangeAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"srt_RangeMember": {
"auth_ref": [
"r288",
"r299",
"r302",
"r449",
"r450",
"r451",
"r452",
"r453",
"r454",
"r455",
"r486",
"r488"
],
"lang": {
"en-us": {
"role": {
"label": "Range [Member]",
"terseLabel": "Statistical Measurement"
}
}
},
"localname": "RangeMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_ScenarioForecastMember": {
"auth_ref": [
"r300"
],
"lang": {
"en-us": {
"role": {
"label": "Scenario Forecast [Member]",
"terseLabel": "Forecast"
}
}
},
"localname": "ScenarioForecastMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_ScenarioUnspecifiedDomain": {
"auth_ref": [
"r300"
],
"lang": {
"en-us": {
"role": {
"label": "Scenario Unspecified [Domain]",
"terseLabel": "Scenario"
}
}
},
"localname": "ScenarioUnspecifiedDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_SegmentGeographicalDomain": {
"auth_ref": [
"r179",
"r180",
"r282",
"r286",
"r487",
"r519",
"r520",
"r521",
"r522",
"r523",
"r524",
"r525",
"r526"
],
"lang": {
"en-us": {
"role": {
"label": "Segment Geographical [Domain]",
"terseLabel": "Geographical"
}
}
},
"localname": "SegmentGeographicalDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationLongLivedAssetsByGeographicAreaDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "domainItemType"
},
"srt_StatementGeographicalAxis": {
"auth_ref": [
"r179",
"r180",
"r282",
"r286",
"r487",
"r518",
"r519",
"r520",
"r521",
"r522",
"r523",
"r524",
"r525",
"r526",
"r527"
],
"lang": {
"en-us": {
"role": {
"label": "Statement Geographical [Axis]",
"terseLabel": "Geographical"
}
}
},
"localname": "StatementGeographicalAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationLongLivedAssetsByGeographicAreaDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "stringItemType"
},
"srt_StatementScenarioAxis": {
"auth_ref": [
"r231",
"r300",
"r445"
],
"lang": {
"en-us": {
"role": {
"label": "Statement Scenario [Axis]",
"terseLabel": "Scenario"
}
}
},
"localname": "StatementScenarioAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"srt_SubsidiariesMember": {
"auth_ref": [
"r296",
"r438",
"r439",
"r442"
],
"lang": {
"en-us": {
"role": {
"label": "Subsidiaries [Member]",
"terseLabel": "Subsidiaries"
}
}
},
"localname": "SubsidiariesMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails"
],
"xbrltype": "domainItemType"
},
"srt_TitleOfIndividualAxis": {
"auth_ref": [
"r186",
"r441"
],
"lang": {
"en-us": {
"role": {
"label": "Title Of Individual [Axis]",
"terseLabel": "Title of Individual"
}
}
},
"localname": "TitleOfIndividualAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"srt_TitleOfIndividualWithRelationshipToEntityDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Title Of Individual With Relationship To Entity [Domain]",
"terseLabel": "Title of Individual"
}
}
},
"localname": "TitleOfIndividualWithRelationshipToEntityDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"synh_A2017CreditAgreementAmendmentNo2RevolvingCreditFacilityDueAugust2024Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Amendment No 2 - Revolving Credit Facility due August 2024.",
"label": "A2017 Credit Agreement Amendment No2 Revolving Credit Facility Due August2024 [Member]",
"terseLabel": "2017 Credit Agreement - Amendment No 2 - Term Loan B Due August 2024"
}
}
},
"localname": "A2017CreditAgreementAmendmentNo2RevolvingCreditFacilityDueAugust2024Member",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"synh_A2017CreditAgreementAmendmentNo2TermLoanADueMarch2024Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "2017 Credit agreement - Amendment No 2 - Term loan A due March 2024.",
"label": "A2017 Credit Agreement Amendment No2 Term Loan A Due March2024 [Member]",
"terseLabel": "2017 Credit Agreement - Amendment No 2 - Term Loan B Due March 2024"
}
}
},
"localname": "A2017CreditAgreementAmendmentNo2TermLoanADueMarch2024Member",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"synh_A2017CreditAgreementAmendmentNo2TermLoanATrancheOneDueMarch2024Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "2017 Credit agreement - Amendment No 2 - Term loan A tranche one due March 2024.",
"label": "A2017 Credit Agreement Amendment No2 Term Loan A Tranche One Due March2024 [Member]",
"terseLabel": "Term Loan A - Tranche One Due March 2024"
}
}
},
"localname": "A2017CreditAgreementAmendmentNo2TermLoanATrancheOneDueMarch2024Member",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails"
],
"xbrltype": "domainItemType"
},
"synh_A2017CreditAgreementAmendmentNo2TermLoanATrancheTwoDueAugust2024Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "2017 Credit agreement - Amendment No 2 - Term loan A tranche two due August 2024.",
"label": "A2017 Credit Agreement Amendment No2 Term Loan A Tranche Two Due August2024 [Member]",
"terseLabel": "Term Loan A - Tranche Two Due August 2024"
}
}
},
"localname": "A2017CreditAgreementAmendmentNo2TermLoanATrancheTwoDueAugust2024Member",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails"
],
"xbrltype": "domainItemType"
},
"synh_A2017CreditAgreementAmendmentNo2TermLoanBDueAugust2024Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "2017 Credit agreement - Amendment No 2 - Term loan B due August 2024.",
"label": "A2017 Credit Agreement Amendment No2 Term Loan B Due August2024 [Member]",
"terseLabel": "2017 Credit Agreement - Amendment No 2 - Term Loan B Due August 2024",
"verboseLabel": "Term Loan B"
}
}
},
"localname": "A2017CreditAgreementAmendmentNo2TermLoanBDueAugust2024Member",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "domainItemType"
},
"synh_A2017CreditAgreementRevolvingCreditFacilityDueAugust2024Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "2017 Credit Agreement Revolving Credit Facility Due August 2024.",
"label": "A2017 Credit Agreement Revolving Credit Facility Due August2024 [Member]",
"terseLabel": "Revolving Credit Facility Due August 2024"
}
}
},
"localname": "A2017CreditAgreementRevolvingCreditFacilityDueAugust2024Member",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"synh_A2017CreditAgreementTermLoanBDueAugust2024Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "2017 Credit agreement term loan B due August 2024.",
"label": "A2017 Credit Agreement Term Loan B Due August2024 [Member]",
"terseLabel": "2017 Credit Agreement - Amendment No 2 - Term Loan B Due August 2024"
}
}
},
"localname": "A2017CreditAgreementTermLoanBDueAugust2024Member",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"synh_AccountsReceivableFinancingAgreementDueOctober2022Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Accounts receivable financing agreement due october 2022.",
"label": "Accounts Receivable Financing Agreement Due October2022 [Member]",
"terseLabel": "Accounts receivable financing agreement due October 2022"
}
}
},
"localname": "AccountsReceivableFinancingAgreementDueOctober2022Member",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "domainItemType"
},
"synh_AccountsReceivableFinancingAgreementDueSeptember2021Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Accounts receivable financing agreement due September 2021.",
"label": "Accounts Receivable Financing Agreement Due September2021 [Member]",
"terseLabel": "Accounts receivable financing agreement due September 2021"
}
}
},
"localname": "AccountsReceivableFinancingAgreementDueSeptember2021Member",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails"
],
"xbrltype": "domainItemType"
},
"synh_AccountsReceivableSecuritizationMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Accounts Receivable Securitization [Member]",
"label": "Accounts Receivable Securitization [Member]",
"terseLabel": "Accounts Receivable Securitization"
}
}
},
"localname": "AccountsReceivableSecuritizationMember",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "domainItemType"
},
"synh_BermudezAndVaitkuvieneActionsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Bermudez And Vaitkuviene Actions [Member]",
"label": "Bermudez And Vaitkuviene Actions [Member]",
"terseLabel": "Bermudez and Vaitkuviene Actions"
}
}
},
"localname": "BermudezAndVaitkuvieneActionsMember",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"synh_BusinessExitCostsAndGainLossOnTerminationOfLease": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Business Exit Costs And (Gain) Loss On Termination Of Lease",
"label": "Business Exit Costs And Gain Loss On Termination Of Lease",
"terseLabel": "Business exit costs and (gain) loss on termination of lease"
}
}
},
"localname": "BusinessExitCostsAndGainLossOnTerminationOfLease",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsLiabilitiesAssociatedWithRestructuringAndOtherCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"synh_CashandCashEquivalentsCashPoolingAgreementCashPoolBorrowings": {
"auth_ref": [
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfCashPoolPositionDetails": {
"order": 10020.0,
"parentTag": "synh_CashandCashEquivalentsCashPoolingAgreementNetCashPosition",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Cash and Cash Equivalents, Cash Pooling Agreement, Cash Pool Borrowings",
"label": "Cashand Cash Equivalents Cash Pooling Agreement Cash Pool Borrowings",
"negatedLabel": "Less: cash borrowings"
}
}
},
"localname": "CashandCashEquivalentsCashPoolingAgreementCashPoolBorrowings",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfCashPoolPositionDetails"
],
"xbrltype": "monetaryItemType"
},
"synh_CashandCashEquivalentsCashPoolingAgreementGrossCashPosition": {
"auth_ref": [
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfCashPoolPositionDetails": {
"order": 10010.0,
"parentTag": "synh_CashandCashEquivalentsCashPoolingAgreementNetCashPosition",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Cash and Cash Equivalents, Cash Pooling Agreement, Gross Cash Position",
"label": "Cashand Cash Equivalents Cash Pooling Agreement Gross Cash Position",
"terseLabel": "Gross cash position"
}
}
},
"localname": "CashandCashEquivalentsCashPoolingAgreementGrossCashPosition",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfCashPoolPositionDetails"
],
"xbrltype": "monetaryItemType"
},
"synh_CashandCashEquivalentsCashPoolingAgreementNetCashPosition": {
"auth_ref": [
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfCashPoolPositionDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Cash and Cash Equivalents, Cash Pooling Agreement, Net Cash Position",
"label": "Cashand Cash Equivalents Cash Pooling Agreement Net Cash Position",
"totalLabel": "Net cash position"
}
}
},
"localname": "CashandCashEquivalentsCashPoolingAgreementNetCashPosition",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfCashPoolPositionDetails"
],
"xbrltype": "monetaryItemType"
},
"synh_ClinicalSolutionsSegmentMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Clinical Solutions Segment [Member]",
"label": "Clinical Solutions Segment [Member]",
"terseLabel": "Clinical Solutions"
}
}
},
"localname": "ClinicalSolutionsSegmentMember",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfGoodwillDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"synh_CommercialSolutionsSegmentMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Commercial Solutions Segment [Member]",
"label": "Commercial Solutions Segment [Member]",
"terseLabel": "Commercial Solutions"
}
}
},
"localname": "CommercialSolutionsSegmentMember",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfGoodwillDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"synh_ContractualObligationNotYetSatisfied": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Contractual obligation not yet satisfied.",
"label": "Contractual Obligation Not Yet Satisfied",
"terseLabel": "Remaining unfunded commitment"
}
}
},
"localname": "ContractualObligationNotYetSatisfied",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetails"
],
"xbrltype": "monetaryItemType"
},
"synh_CostofServicesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Cost of Services [Member]",
"label": "Costof Services [Member]",
"terseLabel": "Direct costs"
}
}
},
"localname": "CostofServicesMember",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"synh_DebtInstrumentCovenantFirstLienLeverageRatioMaximum": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Covenant, First Lien Leverage Ratio, Maximum",
"label": "Debt Instrument Covenant First Lien Leverage Ratio Maximum",
"terseLabel": "Maximum first lien leverage ratio"
}
}
},
"localname": "DebtInstrumentCovenantFirstLienLeverageRatioMaximum",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails"
],
"xbrltype": "pureItemType"
},
"synh_FederalFundsRateMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Federal Funds Rate [Member]",
"label": "Federal Funds Rate [Member]",
"terseLabel": "Federal Funds Rate"
}
}
},
"localname": "FederalFundsRateMember",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails"
],
"xbrltype": "domainItemType"
},
"synh_GeographicInformationTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure for geographic information.",
"label": "Geographic Information [Text Block]",
"terseLabel": "Operations by Geographic Location"
}
}
},
"localname": "GeographicInformationTextBlock",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocation"
],
"xbrltype": "textBlockItemType"
},
"synh_HealthcareAndLifeSciencesIndustryMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Healthcare and life sciences industry.",
"label": "Healthcare And Life Sciences Industry [Member]",
"terseLabel": "Healthcare and Life Sciences Industry"
}
}
},
"localname": "HealthcareAndLifeSciencesIndustryMember",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetails"
],
"xbrltype": "domainItemType"
},
"synh_IllingworthResearchMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Illingworth Research.",
"label": "Illingworth Research [Member]",
"terseLabel": "Illingworth Research Group Acquisition"
}
}
},
"localname": "IllingworthResearchMember",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinationsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"synh_InVentivMergerMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the aggregation and reporting of information related to the Company's merger with InVentiv Health, Inc.",
"label": "In Ventiv Merger [Member]",
"terseLabel": "InVentiv Merger"
}
}
},
"localname": "InVentivMergerMember",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"synh_IncomeTaxesDiscreteTaxExpenseBenefits": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Income Taxes, Discrete Tax Expense Benefits.",
"label": "Income Taxes Discrete Tax Expense Benefits",
"terseLabel": "Discrete tax benefits (expense)"
}
}
},
"localname": "IncomeTaxesDiscreteTaxExpenseBenefits",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"synh_IncreaseDecreaseInAccountsReceivableContractWithCustomerAssetNetCurrentAndContractWithCustomerLiabilityCurrent": {
"auth_ref": [
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10270.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Increase (Decrease) In Accounts Receivable, Contract With Customer Asset, Net Current And Contract With Customer Liability, Current",
"label": "Increase Decrease In Accounts Receivable Contract With Customer Asset Net Current And Contract With Customer Liability Current",
"negatedLabel": "Accounts receivable, unbilled services, and deferred revenue"
}
}
},
"localname": "IncreaseDecreaseInAccountsReceivableContractWithCustomerAssetNetCurrentAndContractWithCustomerLiabilityCurrent",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"synh_InterestRateSwapExpiringJune302021Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Interest rate swap expiring June 30, 2021.",
"label": "Interest Rate Swap Expiring June302021 [Member]",
"terseLabel": "Interest Rate Swap, expiring June 30, 2021"
}
}
},
"localname": "InterestRateSwapExpiringJune302021Member",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"synh_InterestRateSwapExpiringMarch312023Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Interest rate swap expiring March 31, 2023.",
"label": "Interest Rate Swap Expiring March312023 [Member]",
"terseLabel": "Interest Rate Swap, expiring March 31, 2023"
}
}
},
"localname": "InterestRateSwapExpiringMarch312023Member",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"synh_LossContingencyNumberOfActionsTakenByPlaintiff": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Loss Contingency, Number Of Actions Taken By Plaintiff",
"label": "Loss Contingency Number Of Actions Taken By Plaintiff",
"terseLabel": "Number of actions taken by plaintiff"
}
}
},
"localname": "LossContingencyNumberOfActionsTakenByPlaintiff",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
],
"xbrltype": "integerItemType"
},
"synh_NumberOfPrivateEquityFunds": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of private equity funds.",
"label": "Number Of Private Equity Funds",
"terseLabel": "Number of private equity funds"
}
}
},
"localname": "NumberOfPrivateEquityFunds",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetails"
],
"xbrltype": "integerItemType"
},
"synh_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent1": {
"auth_ref": [
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": {
"order": 10020.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss), attributable to parent entity.",
"label": "Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax Portion Attributable To Parent1",
"terseLabel": "Unrealized gain (loss) on derivative instruments, net of income tax expense (benefit) of $2,013 and $(6,639), respectively"
}
}
},
"localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent1",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"synh_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax1": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of tax expense (benefit), after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
"label": "Other Comprehensive Income Loss Derivatives Qualifying As Hedges Tax1",
"negatedLabel": "Income tax benefit related to unrealized gain (loss) on derivative instruments recorded in other comprehensive loss"
}
}
},
"localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax1",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnauditedParenthetical"
],
"xbrltype": "monetaryItemType"
},
"synh_OtherSundryNonoperatingIncomeExpense": {
"auth_ref": [
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherIncomeNetDetails": {
"order": 10030.0,
"parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Other nonoperating income or expense not including foreign currency gain or loss.",
"label": "Other Sundry Nonoperating Income Expense",
"negatedLabel": "Other, net"
}
}
},
"localname": "OtherSundryNonoperatingIncomeExpense",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherIncomeNetDetails"
],
"xbrltype": "monetaryItemType"
},
"synh_PercentageOfOutstandingSharesPurchase": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of Outstanding Shares Purchase.",
"label": "Percentage Of Outstanding Shares Purchase",
"terseLabel": "Percentage of Outstanding Shares Purchase"
}
}
},
"localname": "PercentageOfOutstandingSharesPurchase",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinationsNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"synh_ProceedsFromInvestmentsInUnconsolidatedAffiliates": {
"auth_ref": [
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10170.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Proceeds from (investments in) unconsolidated affiliates.",
"label": "Proceeds From Investments In Unconsolidated Affiliates",
"negatedLabel": "Proceeds from (investments in) unconsolidated affiliates"
}
}
},
"localname": "ProceedsFromInvestmentsInUnconsolidatedAffiliates",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"synh_ReceivablesFinancingAgreementPrepaymentOfLoanFacilityNoticeTerm": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Receivables Financing Agreement, Prepayment of Loan Facility, Notice Term",
"label": "Receivables Financing Agreement Prepayment Of Loan Facility Notice Term",
"terseLabel": "Prepay notice, term"
}
}
},
"localname": "ReceivablesFinancingAgreementPrepaymentOfLoanFacilityNoticeTerm",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails"
],
"xbrltype": "durationItemType"
},
"synh_ReceivablesFinancingAgreementTerminationOrReductionToFacilityLimitNoticeTerm": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Receivables Financing Agreement, Termination Or Reduction To Facility Limit Notice Term",
"label": "Receivables Financing Agreement Termination Or Reduction To Facility Limit Notice Term",
"terseLabel": "Termination or reduction to limit notice, term"
}
}
},
"localname": "ReceivablesFinancingAgreementTerminationOrReductionToFacilityLimitNoticeTerm",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails"
],
"xbrltype": "durationItemType"
},
"synh_ReceivablesNetCurrentAndContractWithCustomerAssetNetCurrent": {
"auth_ref": [
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccountsReceivableAndUnbilledServicesNetDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10300.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Receivables, Net, Current And Contract With Customer, Asset, Net, Current",
"label": "Receivables Net Current And Contract With Customer Asset Net Current",
"terseLabel": "Accounts receivable and unbilled services, net",
"totalLabel": "Accounts receivable and unbilled services, net"
}
}
},
"localname": "ReceivablesNetCurrentAndContractWithCustomerAssetNetCurrent",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccountsReceivableAndUnbilledServicesNetDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"synh_RelatedPartyTransactionNumberOfCounterparties": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Related Party Transaction, Number Of Counterparties",
"label": "Related Party Transaction Number Of Counterparties",
"terseLabel": "Number of counterparties"
}
}
},
"localname": "RelatedPartyTransactionNumberOfCounterparties",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
],
"xbrltype": "integerItemType"
},
"synh_RestructuringChargeIncludingOtherCosts": {
"auth_ref": [
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": 10130.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Restructuring Charge, Including Other Costs",
"label": "Restructuring Charge Including Other Costs",
"terseLabel": "Restructuring and other costs"
}
}
},
"localname": "RestructuringChargeIncludingOtherCosts",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "monetaryItemType"
},
"synh_RestructuringChargeIncludingOtherCosts1": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Restructuring Charge Including Other Costs.",
"label": "Restructuring Charge Including Other Costs1",
"terseLabel": "Expenses incurred"
}
}
},
"localname": "RestructuringChargeIncludingOtherCosts1",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsLiabilitiesAssociatedWithRestructuringAndOtherCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"synh_RevenuePerformanceObligationContractTerm": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Revenue, Performance Obligation, Contract Term",
"label": "Revenue Performance Obligation Contract Term",
"terseLabel": "Contract term"
}
}
},
"localname": "RevenuePerformanceObligationContractTerm",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"synh_ScheduleOfCashPoolPositionTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule Of Cash Pool Position [Table Text Block]",
"label": "Schedule Of Cash Pool Position Table [Text Block]",
"terseLabel": "Schedule Of Cash Pool Position"
}
}
},
"localname": "ScheduleOfCashPoolPositionTableTextBlock",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables"
],
"xbrltype": "textBlockItemType"
},
"synh_SeniorUnsecuredNoteDue2029Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Senior unsecured note due 2029.",
"label": "Senior Unsecured Note Due2029 [Member]",
"terseLabel": "3.625% Senior Unsecured Notes due 2029"
}
}
},
"localname": "SeniorUnsecuredNoteDue2029Member",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails"
],
"xbrltype": "domainItemType"
},
"synh_SeniorUnsecuredNotesDue2029Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "3.625% senior unsecured notes due 2029.",
"label": "Senior Unsecured Notes Due2029 [Member]",
"terseLabel": "3.625% Senior Unsecured Notes due 2029"
}
}
},
"localname": "SeniorUnsecuredNotesDue2029Member",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "domainItemType"
},
"synh_StockRepurchaseProgramSharesPurchasedValue": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Stock Repurchase Program, Shares Purchased, Value",
"label": "Stock Repurchase Program Shares Purchased Value",
"terseLabel": "Stock repurchase program, shares purchased, value"
}
}
},
"localname": "StockRepurchaseProgramSharesPurchasedValue",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityRepurchaseActivityDetails"
],
"xbrltype": "monetaryItemType"
},
"synh_StockholdersEquityAttributableToParentAdjustedBalance": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Stockholders' Equity Attributable To Parent, Adjusted Balance",
"label": "Stockholders Equity Attributable To Parent Adjusted Balance",
"terseLabel": "Adjusted beginning balance"
}
}
},
"localname": "StockholdersEquityAttributableToParentAdjustedBalance",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "monetaryItemType"
},
"synh_SynteractAcquisitionMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Synteract acquisition.",
"label": "Synteract Acquisition [Member]",
"terseLabel": "Synteract Acquisition"
}
}
},
"localname": "SynteractAcquisitionMember",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinationsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"synh_TermLoanATrancheOneDueMarch2024Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Term Loan A tranche one due march 2024.",
"label": "Term Loan A Tranche One Due March2024 [Member]",
"terseLabel": "Term Loan A - tranche one due March 2024"
}
}
},
"localname": "TermLoanATrancheOneDueMarch2024Member",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "domainItemType"
},
"synh_TermLoanATrancheTwoDueAugust2024Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Term Loan A tranche two due August 2024.",
"label": "Term Loan A Tranche Two Due August2024 [Member]",
"terseLabel": "Term Loan A - tranche two due August 2024"
}
}
},
"localname": "TermLoanATrancheTwoDueAugust2024Member",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "domainItemType"
},
"synh_TermLoanMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Term Loan [Member]",
"label": "Term Loan [Member]",
"terseLabel": "Term Loan"
}
}
},
"localname": "TermLoanMember",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"synh_TradeReceivablesSold": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of trade receivables sold.",
"label": "Trade Receivables Sold",
"terseLabel": "Trade receivables sold"
}
}
},
"localname": "TradeReceivablesSold",
"nsuri": "http://www.syneoshealth.com/20210331",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "A O C I Attributable To Parent Net Of Tax Roll Forward",
"terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
}
}
},
"localname": "AOCIAttributableToParentNetOfTaxRollForward",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccumulatedOtherComprehensiveLossNetOfTaxesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccountingPoliciesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Abstract]"
}
}
},
"localname": "AccountingPoliciesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_AccountingStandardsUpdateExtensibleList": {
"auth_ref": [
"r105",
"r106",
"r107",
"r108",
"r192",
"r193",
"r194",
"r195",
"r196",
"r197",
"r307",
"r308",
"r309",
"r310",
"r311",
"r312",
"r313",
"r314",
"r334",
"r335",
"r489",
"r490",
"r491",
"r492",
"r493",
"r494",
"r495",
"r496",
"r497",
"r498",
"r499",
"r500"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates amendment to accounting standards.",
"label": "Accounting Standards Update Extensible List",
"terseLabel": "Accounting Standards Update [Extensible List]"
}
}
},
"localname": "AccountingStandardsUpdateExtensibleList",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "extensibleListItemType"
},
"us-gaap_AccountsPayableCurrent": {
"auth_ref": [
"r23"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10160.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accounts Payable Current",
"terseLabel": "Accounts payable"
}
}
},
"localname": "AccountsPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsReceivableGrossCurrent": {
"auth_ref": [
"r187",
"r188"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccountsReceivableAndUnbilledServicesNetDetails": {
"order": 10010.0,
"parentTag": "synh_ReceivablesNetCurrentAndContractWithCustomerAssetNetCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
"label": "Accounts Receivable Gross Current",
"terseLabel": "Accounts receivable billed"
}
}
},
"localname": "AccountsReceivableGrossCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccountsReceivableAndUnbilledServicesNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsReceivableMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
"label": "Accounts Receivable [Member]",
"terseLabel": "Accounts Receivable"
}
}
},
"localname": "AccountsReceivableMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureConcentrationOfCreditRiskNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccruedLiabilitiesCurrent": {
"auth_ref": [
"r26"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10170.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued Liabilities Current",
"terseLabel": "Accrued expenses"
}
}
},
"localname": "AccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedLiabilitiesMember": {
"auth_ref": [
"r26"
],
"lang": {
"en-us": {
"role": {
"documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
"label": "Accrued Liabilities [Member]",
"terseLabel": "Accrued expenses"
}
}
},
"localname": "AccruedLiabilitiesMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
"auth_ref": [
"r44",
"r53",
"r364"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
"label": "Accumulated Gain Loss Net Cash Flow Hedge Parent [Member]",
"terseLabel": "Derivative Instruments"
}
}
},
"localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccumulatedOtherComprehensiveLossNetOfTaxesDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTaxEffectsAllocatedToEachComponentOfOtherComprehensiveLossIncomeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Accumulated Other Comprehensive Income Loss [Line Items]",
"terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccumulatedOtherComprehensiveLossNetOfTaxesDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTaxEffectsAllocatedToEachComponentOfOtherComprehensiveLossIncomeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
"auth_ref": [
"r15",
"r41",
"r43",
"r44",
"r475",
"r496",
"r500"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10070.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
"label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
"terseLabel": "Accumulated other comprehensive loss, net of taxes"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
"auth_ref": [
"r418",
"r419",
"r420",
"r421",
"r422",
"r425"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
"label": "Accumulated Other Comprehensive Income Loss [Table]",
"terseLabel": "Accumulated Other Comprehensive Income Loss [Table]"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccumulatedOtherComprehensiveLossNetOfTaxesDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTaxEffectsAllocatedToEachComponentOfOtherComprehensiveLossIncomeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
"auth_ref": [
"r40",
"r44",
"r46",
"r101",
"r102",
"r103",
"r365",
"r491",
"r492"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
"label": "Accumulated Other Comprehensive Income [Member]",
"terseLabel": "Accumulated Other Comprehensive Loss"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccumulatedOtherComprehensiveLossNetOfTaxesDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccumulatedTranslationAdjustmentMember": {
"auth_ref": [
"r38",
"r44",
"r46",
"r365",
"r419",
"r420",
"r421",
"r422",
"r425"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
"label": "Accumulated Translation Adjustment [Member]",
"terseLabel": "Foreign Currency Translation"
}
}
},
"localname": "AccumulatedTranslationAdjustmentMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccumulatedOtherComprehensiveLossNetOfTaxesDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTaxEffectsAllocatedToEachComponentOfOtherComprehensiveLossIncomeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
"label": "Additional Financial Information Disclosure [Text Block]",
"terseLabel": "Financial Statement Details"
}
}
},
"localname": "AdditionalFinancialInformationDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetails"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_AdditionalPaidInCapital": {
"auth_ref": [
"r13",
"r314"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10060.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
"label": "Additional Paid In Capital",
"terseLabel": "Additional paid-in capital"
}
}
},
"localname": "AdditionalPaidInCapital",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
"r101",
"r102",
"r103",
"r311",
"r312",
"r313"
],
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid In Capital [Member]",
"terseLabel": "Additional Paid-in Capital"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
"auth_ref": [
"r303",
"r304",
"r316",
"r317"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
"label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
"terseLabel": "Share-based compensation"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
"terseLabel": "Adjustments to reconcile net income to net cash provided by (used in) operating activities:"
}
}
},
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AllocatedShareBasedCompensationExpense": {
"auth_ref": [
"r304",
"r305",
"r315"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
"label": "Allocated Share Based Compensation Expense",
"terseLabel": "Share-based compensation expense"
}
}
},
"localname": "AllocatedShareBasedCompensationExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
"auth_ref": [
"r19",
"r189",
"r198"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccountsReceivableAndUnbilledServicesNetDetails": {
"order": 10040.0,
"parentTag": "synh_ReceivablesNetCurrentAndContractWithCustomerAssetNetCurrent",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
"label": "Allowance For Doubtful Accounts Receivable Current",
"negatedLabel": "Less: Allowance for doubtful accounts"
}
}
},
"localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccountsReceivableAndUnbilledServicesNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AlternativeInvestment": {
"auth_ref": [
"r389",
"r402"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
"order": 10040.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.",
"label": "Alternative Investment",
"terseLabel": "Partnership interest"
}
}
},
"localname": "AlternativeInvestment",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AmortizationOfIntangibleAssets": {
"auth_ref": [
"r80",
"r212",
"r214"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": 10150.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
"label": "Amortization Of Intangible Assets",
"terseLabel": "Amortization"
}
}
},
"localname": "AmortizationOfIntangibleAssets",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"auth_ref": [
"r129"
],
"lang": {
"en-us": {
"role": {
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
"label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
"terseLabel": "Anti-dillutive shares outstanding excluded from the computation of diluted earnings per share"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareNarrativeDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r87",
"r159",
"r166",
"r173",
"r191",
"r362",
"r366",
"r411",
"r459",
"r473"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets",
"totalLabel": "Total assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets [Abstract]",
"terseLabel": "ASSETS"
}
}
},
"localname": "AssetsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r3",
"r4",
"r34",
"r87",
"r191",
"r362",
"r366",
"r411"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10220.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets Current",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets Current [Abstract]",
"terseLabel": "Current assets:"
}
}
},
"localname": "AssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsFairValueDisclosure": {
"auth_ref": [
"r390"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets Fair Value Disclosure",
"totalLabel": "Total assets"
}
}
},
"localname": "AssetsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsFairValueDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets Fair Value Disclosure [Abstract]",
"terseLabel": "Assets:"
}
}
},
"localname": "AssetsFairValueDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_BalanceSheetLocationAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location on balance sheet (statement of financial position).",
"label": "Balance Sheet Location [Axis]",
"terseLabel": "Balance Sheet Location"
}
}
},
"localname": "BalanceSheetLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_BalanceSheetLocationDomain": {
"auth_ref": [
"r375",
"r378"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the balance sheet (statement of financial position).",
"label": "Balance Sheet Location [Domain]",
"terseLabel": "Balance Sheet Location"
}
}
},
"localname": "BalanceSheetLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
"label": "Basis Of Accounting Policy Policy [Text Block]",
"terseLabel": "Unaudited Interim Financial Information"
}
}
},
"localname": "BasisOfAccountingPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBasisOfPresentationAndChangesInSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
"auth_ref": [
"r100"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
"label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
"terseLabel": "Basis of Presentation and Changes in Significant Accounting Policies"
}
}
},
"localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBasisOfPresentationAndChangesInSignificantAccountingPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_BusinessAcquisitionAcquireeDomain": {
"auth_ref": [
"r298",
"r301"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
"label": "Business Acquisition Acquiree [Domain]",
"terseLabel": "Business Acquisition, Acquiree"
}
}
},
"localname": "BusinessAcquisitionAcquireeDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_BusinessAcquisitionAxis": {
"auth_ref": [
"r298",
"r301",
"r349",
"r350"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by business combination or series of individually immaterial business combinations.",
"label": "Business Acquisition [Axis]",
"terseLabel": "Business Acquisition"
}
}
},
"localname": "BusinessAcquisitionAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Date when the business acquisition agreement was executed, in CCYY-MM-DD format.",
"label": "Business Acquisition Date Of Acquisition Agreement1",
"terseLabel": "Date of Acquisition"
}
}
},
"localname": "BusinessAcquisitionDateOfAcquisitionAgreement1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinationsNarrativeDetails"
],
"xbrltype": "dateItemType"
},
"us-gaap_BusinessAcquisitionLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Business Acquisition [Line Items]",
"terseLabel": "Business Acquisition [Line Items]"
}
}
},
"localname": "BusinessAcquisitionLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinationsNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_BusinessAcquisitionNameOfAcquiredEntity": {
"auth_ref": [
"r348"
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the acquired entity.",
"label": "Business Acquisition Name Of Acquired Entity",
"terseLabel": "Name of acquired entity"
}
}
},
"localname": "BusinessAcquisitionNameOfAcquiredEntity",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinationsNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_BusinessCombinationConsiderationTransferred1": {
"auth_ref": [
"r353",
"r354",
"r356"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
"label": "Business Combination Consideration Transferred1",
"terseLabel": "Aggregate purchase price for the acquisition"
}
}
},
"localname": "BusinessCombinationConsiderationTransferred1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinationsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": {
"auth_ref": [
"r79",
"r358"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10240.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset.",
"label": "Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1",
"negatedLabel": "Fair value adjustment of contingent obligations"
}
}
},
"localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_BusinessCombinationContingentConsiderationLiability": {
"auth_ref": [
"r352",
"r355",
"r357"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
"order": 10020.0,
"parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
"label": "Business Combination Contingent Consideration Liability",
"terseLabel": "Contingent obligations related to business combinations"
}
}
},
"localname": "BusinessCombinationContingentConsiderationLiability",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_BusinessCombinationDisclosureTextBlock": {
"auth_ref": [
"r359"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
"label": "Business Combination Disclosure [Text Block]",
"terseLabel": "Business Combinations"
}
}
},
"localname": "BusinessCombinationDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinations"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
"auth_ref": [
"r351"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
"label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill",
"terseLabel": "Intangible assets"
}
}
},
"localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinationsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_BusinessCombinationsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Business Combinations [Abstract]"
}
}
},
"localname": "BusinessCombinationsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_BusinessRestructuringReservesMember": {
"auth_ref": [
"r99"
],
"lang": {
"en-us": {
"role": {
"documentation": "Reserve for expected cost from exit or disposal obligation excluding cost pertaining to entity newly acquired in business combination and asset retirement obligation. Includes, but is not limited to, cost for one-time termination benefit, termination of contract, and consolidating or closing facility.",
"label": "Business Restructuring Reserves [Member]",
"terseLabel": "Business Restructuring Reserves"
}
}
},
"localname": "BusinessRestructuringReservesMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsLiabilitiesAssociatedWithRestructuringAndOtherCostsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CapitalLeaseObligationsCurrent": {
"auth_ref": [
"r7",
"r432",
"r433"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10210.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.",
"label": "Capital Lease Obligations Current",
"terseLabel": "Current portion of finance lease obligations"
}
}
},
"localname": "CapitalLeaseObligationsCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CapitalLeaseObligationsNoncurrent": {
"auth_ref": [
"r28",
"r432",
"r433"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10130.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.",
"label": "Capital Lease Obligations Noncurrent",
"terseLabel": "Finance lease long-term obligations"
}
}
},
"localname": "CapitalLeaseObligationsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
"auth_ref": [
"r406",
"r407"
],
"lang": {
"en-us": {
"role": {
"documentation": "Measured as reported on the statement of financial position (balance sheet).",
"label": "Carrying Reported Amount Fair Value Disclosure [Member]",
"terseLabel": "Reported Value Measurement"
}
}
},
"localname": "CarryingReportedAmountFairValueDisclosureMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CashAcquiredFromAcquisition": {
"auth_ref": [
"r67"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
"label": "Cash Acquired From Acquisition",
"terseLabel": "Cash acquired"
}
}
},
"localname": "CashAcquiredFromAcquisition",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinationsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r77",
"r82",
"r83"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10290.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
"periodEndLabel": "Cash, cash equivalents, and restricted cash - end of period",
"periodStartLabel": "Cash, cash equivalents, and restricted cash - beginning of period",
"terseLabel": "Cash, cash equivalents, and restricted cash"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"auth_ref": [
"r77",
"r417"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
"totalLabel": "Net change in cash, cash equivalents, and restricted cash"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashFlowHedgingMember": {
"auth_ref": [
"r372"
],
"lang": {
"en-us": {
"role": {
"documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
"label": "Cash Flow Hedging [Member]",
"terseLabel": "Cash Flow Hedging"
}
}
},
"localname": "CashFlowHedgingMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ClassOfStockDomain": {
"auth_ref": [
"r85",
"r87",
"r119",
"r123",
"r124",
"r126",
"r128",
"r136",
"r137",
"r138",
"r191",
"r411"
],
"lang": {
"en-us": {
"role": {
"documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
"label": "Class Of Stock [Domain]",
"terseLabel": "Class of Stock"
}
}
},
"localname": "ClassOfStockDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityRepurchaseActivityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ClassOfStockLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Class Of Stock [Line Items]",
"terseLabel": "Class of Stock [Line Items]"
}
}
},
"localname": "ClassOfStockLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityRepurchaseActivityDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquitySharesOfCommonStockOutstandingDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CommitmentsAndContingencies": {
"auth_ref": [
"r30",
"r230",
"r463",
"r479"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10020.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
"label": "Commitments And Contingencies",
"terseLabel": "Commitments and contingencies (Note 16)"
}
}
},
"localname": "CommitmentsAndContingencies",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Commitments And Contingencies Disclosure [Abstract]"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
"auth_ref": [
"r227",
"r228",
"r229",
"r237"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for commitments and contingencies.",
"label": "Commitments And Contingencies Disclosure [Text Block]",
"terseLabel": "Commitments and Contingencies"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CommonClassAMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Classification of common stock representing ownership interest in a corporation.",
"label": "Common Class A [Member]",
"terseLabel": "Common Class A [Member]"
}
}
},
"localname": "CommonClassAMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r101",
"r102"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock [Member]",
"terseLabel": "Common Stock"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityRepurchaseActivityDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquitySharesOfCommonStockOutstandingDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r12"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common Stock Par Or Stated Value Per Share",
"terseLabel": "Common stock par value (USD per share)"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r12"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common Stock Shares Authorized",
"terseLabel": "Common stock shares authorized (in shares)"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r12"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common Stock Shares Issued",
"terseLabel": "Common stock shares issued (in shares)"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesOutstanding": {
"auth_ref": [
"r12",
"r250"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
"label": "Common Stock Shares Outstanding",
"terseLabel": "Common stock shares outstanding (in shares)"
}
}
},
"localname": "CommonStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValue": {
"auth_ref": [
"r12"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10050.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Common Stock Value",
"terseLabel": "Common stock, $0.01 par value; 600,000 shares authorized, 104,226 and 103,935 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively"
}
}
},
"localname": "CommonStockValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTax": {
"auth_ref": [
"r49",
"r51",
"r52",
"r58",
"r467",
"r481"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive Income Net Of Tax",
"totalLabel": "Comprehensive income (loss)"
}
}
},
"localname": "ComprehensiveIncomeNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConcentrationRiskBenchmarkDomain": {
"auth_ref": [
"r142",
"r143",
"r184",
"r408",
"r409"
],
"lang": {
"en-us": {
"role": {
"documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
"label": "Concentration Risk Benchmark [Domain]",
"terseLabel": "Concentration Risk Benchmark"
}
}
},
"localname": "ConcentrationRiskBenchmarkDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureConcentrationOfCreditRiskNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConcentrationRiskByBenchmarkAxis": {
"auth_ref": [
"r142",
"r143",
"r184",
"r408",
"r409",
"r501"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by benchmark of concentration risk.",
"label": "Concentration Risk By Benchmark [Axis]",
"terseLabel": "Concentration Risk Benchmark"
}
}
},
"localname": "ConcentrationRiskByBenchmarkAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureConcentrationOfCreditRiskNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskByTypeAxis": {
"auth_ref": [
"r142",
"r143",
"r184",
"r408",
"r409",
"r501"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
"label": "Concentration Risk By Type [Axis]",
"terseLabel": "Concentration Risk Type"
}
}
},
"localname": "ConcentrationRiskByTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureConcentrationOfCreditRiskNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskDisclosureTextBlock": {
"auth_ref": [
"r145"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
"label": "Concentration Risk Disclosure [Text Block]",
"terseLabel": "Concentration of Credit Risk"
}
}
},
"localname": "ConcentrationRiskDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureConcentrationOfCreditRisk"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ConcentrationRiskLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Concentration Risk [Line Items]",
"terseLabel": "Concentration Risk"
}
}
},
"localname": "ConcentrationRiskLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureConcentrationOfCreditRiskNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskPercentage1": {
"auth_ref": [
"r142",
"r143",
"r184",
"r408",
"r409"
],
"lang": {
"en-us": {
"role": {
"documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
"label": "Concentration Risk Percentage1",
"terseLabel": "Concentration risk percentage"
}
}
},
"localname": "ConcentrationRiskPercentage1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureConcentrationOfCreditRiskNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ConcentrationRiskTable": {
"auth_ref": [
"r139",
"r142",
"r143",
"r144",
"r408",
"r410"
],
"lang": {
"en-us": {
"role": {
"documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
"label": "Concentration Risk [Table]",
"terseLabel": "Concentration Risk [Table]"
}
}
},
"localname": "ConcentrationRiskTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureConcentrationOfCreditRiskNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskTypeDomain": {
"auth_ref": [
"r142",
"r143",
"r184",
"r408",
"r409"
],
"lang": {
"en-us": {
"role": {
"documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
"label": "Concentration Risk Type [Domain]",
"terseLabel": "Concentration Risk Type"
}
}
},
"localname": "ConcentrationRiskTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureConcentrationOfCreditRiskNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ContractWithCustomerAssetNetCurrent": {
"auth_ref": [
"r260",
"r262",
"r283"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccountsReceivableAndUnbilledServicesNetDetails": {
"order": 10030.0,
"parentTag": "synh_ReceivablesNetCurrentAndContractWithCustomerAssetNetCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
"label": "Contract With Customer Asset Net Current",
"terseLabel": "Contract assets"
}
}
},
"localname": "ContractWithCustomerAssetNetCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccountsReceivableAndUnbilledServicesNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityCurrent": {
"auth_ref": [
"r260",
"r261",
"r283"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10180.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
"label": "Contract With Customer Liability Current",
"terseLabel": "Deferred revenue"
}
}
},
"localname": "ContractWithCustomerLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
"auth_ref": [
"r284"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
"label": "Contract With Customer Liability Revenue Recognized",
"terseLabel": "Revenue recognized, included in contract liabilities balance at beginning of period"
}
}
},
"localname": "ContractWithCustomerLiabilityRevenueRecognized",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
"auth_ref": [
"r269"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
"label": "Contract With Customer Performance Obligation Satisfied In Previous Period",
"terseLabel": "Increase (decrease) in revenue recognized, allocated to performance obligation partially satisfied in previous periods"
}
}
},
"localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractualObligation": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
"label": "Contractual Obligation",
"terseLabel": "Commitment to invest a limited partner in private equity funds"
}
}
},
"localname": "ContractualObligation",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CorporateNonSegmentMember": {
"auth_ref": [
"r164",
"r165",
"r166",
"r167",
"r169",
"r175",
"r177"
],
"lang": {
"en-us": {
"role": {
"documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
"label": "Corporate Non Segment [Member]",
"terseLabel": "Corporate"
}
}
},
"localname": "CorporateNonSegmentMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CostOfGoodsAndServicesSold": {
"auth_ref": [
"r63",
"r456"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": 10110.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
"label": "Cost Of Goods And Services Sold",
"terseLabel": "Direct costs (exclusive of depreciation and amortization)"
}
}
},
"localname": "CostOfGoodsAndServicesSold",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostsAndExpenses": {
"auth_ref": [
"r61"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": 10100.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Total costs of sales and operating expenses for the period.",
"label": "Costs And Expenses",
"totalLabel": "Total operating expenses"
}
}
},
"localname": "CostsAndExpenses",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CreditFacilityAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
"label": "Credit Facility [Axis]",
"terseLabel": "Credit Facility"
}
}
},
"localname": "CreditFacilityAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CreditFacilityDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
"label": "Credit Facility [Domain]",
"terseLabel": "Credit Facility"
}
}
},
"localname": "CreditFacilityDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CustomerConcentrationRiskMember": {
"auth_ref": [
"r140",
"r184"
],
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
"label": "Customer Concentration Risk [Member]",
"terseLabel": "Customer Concentration Risk"
}
}
},
"localname": "CustomerConcentrationRiskMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureConcentrationOfCreditRiskNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Debt Disclosure [Abstract]"
}
}
},
"localname": "DebtDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_DebtDisclosureTextBlock": {
"auth_ref": [
"r246"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
"label": "Debt Disclosure [Text Block]",
"terseLabel": "Long-Term Debt Obligations"
}
}
},
"localname": "DebtDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligations"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DebtInstrumentAxis": {
"auth_ref": [
"r7",
"r8",
"r9",
"r460",
"r461",
"r472"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
"label": "Debt Instrument [Axis]",
"terseLabel": "Debt Instrument"
}
}
},
"localname": "DebtInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
"label": "Debt Instrument Basis Spread On Variable Rate1",
"terseLabel": "Basis spread on variable rate"
}
}
},
"localname": "DebtInstrumentBasisSpreadOnVariableRate1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentCarryingAmount": {
"auth_ref": [
"r9",
"r242",
"r461",
"r472"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails": {
"order": 10010.0,
"parentTag": "us-gaap_LongTermDebtNoncurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
"label": "Debt Instrument Carrying Amount",
"terseLabel": "Total debt obligations"
}
}
},
"localname": "DebtInstrumentCarryingAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentFaceAmount": {
"auth_ref": [
"r428",
"r431"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Face (par) amount of debt instrument at time of issuance.",
"label": "Debt Instrument Face Amount",
"terseLabel": "Term loan facility"
}
}
},
"localname": "DebtInstrumentFaceAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Debt Instrument [Line Items]",
"terseLabel": "Debt Instrument [Line Items]"
}
}
},
"localname": "DebtInstrumentLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentNameDomain": {
"auth_ref": [
"r28"
],
"lang": {
"en-us": {
"role": {
"documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
"label": "Debt Instrument Name [Domain]",
"terseLabel": "Debt Instrument, Name"
}
}
},
"localname": "DebtInstrumentNameDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
"auth_ref": [
"r28"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the required periodic payments applied to principal.",
"label": "Debt Instrument Periodic Payment Principal",
"terseLabel": "Principal payment"
}
}
},
"localname": "DebtInstrumentPeriodicPaymentPrincipal",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentTable": {
"auth_ref": [
"r28",
"r90",
"r251",
"r254",
"r255",
"r256",
"r427",
"r428",
"r431",
"r471"
],
"lang": {
"en-us": {
"role": {
"documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Debt Instrument [Table]",
"terseLabel": "Debt Instrument [Table]"
}
}
},
"localname": "DebtInstrumentTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
"auth_ref": [
"r427",
"r428",
"r429",
"r430",
"r431"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails": {
"order": 10070.0,
"parentTag": "us-gaap_LongTermDebt",
"weight": -1.0
},
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails": {
"order": 10020.0,
"parentTag": "us-gaap_LongTermDebtNoncurrent",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after accumulated amortization, of debt discount (premium).",
"label": "Debt Instrument Unamortized Discount Premium Net",
"negatedLabel": "Less: Term loan original issuance discount"
}
}
},
"localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtLongtermAndShorttermCombinedAmount": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
"label": "Debt Longterm And Shortterm Combined Amount",
"terseLabel": "Long-term debt, carrying value"
}
}
},
"localname": "DebtLongtermAndShorttermCombinedAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredFinanceCostsNet": {
"auth_ref": [
"r22",
"r429"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails": {
"order": 10060.0,
"parentTag": "us-gaap_LongTermDebt",
"weight": -1.0
},
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails": {
"order": 10030.0,
"parentTag": "us-gaap_LongTermDebtNoncurrent",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
"label": "Deferred Finance Costs Net",
"negatedLabel": "Less: Unamortized deferred issuance costs"
}
}
},
"localname": "DeferredFinanceCostsNet",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredIncomeTaxAssetsNet": {
"auth_ref": [
"r319",
"r320"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10270.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
"label": "Deferred Income Tax Assets Net",
"terseLabel": "Deferred income tax assets"
}
}
},
"localname": "DeferredIncomeTaxAssetsNet",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredIncomeTaxExpenseBenefit": {
"auth_ref": [
"r80",
"r88",
"r332",
"r338",
"r339",
"r340"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10220.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
"label": "Deferred Income Tax Expense Benefit",
"terseLabel": "(Benefit from) provision for deferred income taxes"
}
}
},
"localname": "DeferredIncomeTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredIncomeTaxLiabilitiesNet": {
"auth_ref": [
"r319",
"r320"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10140.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
"label": "Deferred Income Tax Liabilities Net",
"terseLabel": "Deferred income tax liabilities"
}
}
},
"localname": "DeferredIncomeTaxLiabilitiesNet",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_Depreciation": {
"auth_ref": [
"r80",
"r215"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": 10140.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
"label": "Depreciation",
"terseLabel": "Depreciation"
}
}
},
"localname": "Depreciation",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DepreciationAmortizationAndAccretionNet": {
"auth_ref": [
"r80"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.",
"label": "Depreciation Amortization And Accretion Net",
"terseLabel": "Depreciation and amortization"
}
}
},
"localname": "DepreciationAmortizationAndAccretionNet",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DepreciationDepletionAndAmortization": {
"auth_ref": [
"r80",
"r154"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10190.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
"label": "Depreciation Depletion And Amortization",
"terseLabel": "Depreciation and amortization"
}
}
},
"localname": "DepreciationDepletionAndAmortization",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeBasisSpreadOnVariableRate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The percentage points added to the reference rate to compute the variable rate on the interest rate derivative.",
"label": "Derivative Basis Spread On Variable Rate",
"terseLabel": "Adjusted Eurocurrency Rate Spread"
}
}
},
"localname": "DerivativeBasisSpreadOnVariableRate",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DerivativeContractTypeDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
"label": "Derivative Contract Type [Domain]",
"terseLabel": "Derivative Contract"
}
}
},
"localname": "DerivativeContractTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DerivativeInstrumentRiskAxis": {
"auth_ref": [
"r376",
"r377",
"r380",
"r382"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of derivative contract.",
"label": "Derivative Instrument Risk [Axis]",
"terseLabel": "Derivative Instrument"
}
}
},
"localname": "DerivativeInstrumentRiskAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Derivative Instruments And Hedging Activities Disclosure [Abstract]"
}
}
},
"localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
"auth_ref": [
"r388"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
"label": "Derivative Instruments And Hedging Activities Disclosure [Text Block]",
"terseLabel": "Derivatives"
}
}
},
"localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivatives"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
"auth_ref": [
"r373",
"r376",
"r380"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of hedging relationship.",
"label": "Derivative Instruments Gain Loss By Hedging Relationship [Axis]",
"terseLabel": "Hedging Relationship"
}
}
},
"localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeLiabilities": {
"auth_ref": [
"r35",
"r36",
"r405"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
"order": 10010.0,
"parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
"label": "Derivative Liabilities",
"terseLabel": "Derivative instruments",
"totalLabel": "Derivative liability"
}
}
},
"localname": "DerivativeLiabilities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeLiabilitiesCurrent": {
"auth_ref": [
"r35"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails": {
"order": 10010.0,
"parentTag": "us-gaap_DerivativeLiabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
"label": "Derivative Liabilities Current",
"terseLabel": "Derivative asset - current"
}
}
},
"localname": "DerivativeLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeLiabilitiesNoncurrent": {
"auth_ref": [
"r35"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails": {
"order": 10020.0,
"parentTag": "us-gaap_DerivativeLiabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
"label": "Derivative Liabilities Noncurrent",
"terseLabel": "Derivative liability - non-current"
}
}
},
"localname": "DerivativeLiabilitiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Derivative [Line Items]",
"terseLabel": "Derivative [Line Items]"
}
}
},
"localname": "DerivativeLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeNotionalAmount": {
"auth_ref": [
"r369",
"r371"
],
"lang": {
"en-us": {
"role": {
"documentation": "Nominal or face amount used to calculate payment on derivative.",
"label": "Derivative Notional Amount",
"terseLabel": "Notional amount"
}
}
},
"localname": "DerivativeNotionalAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeTable": {
"auth_ref": [
"r368",
"r370",
"r371",
"r373",
"r374",
"r379",
"r380",
"r384",
"r385",
"r387"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
"label": "Derivative [Table]",
"terseLabel": "Derivative [Table]"
}
}
},
"localname": "DerivativeTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativesFairValueLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Derivatives Fair Value [Line Items]",
"terseLabel": "Derivatives, Fair Value [Line Items]"
}
}
},
"localname": "DerivativesFairValueLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DesignatedAsHedgingInstrumentMember": {
"auth_ref": [
"r373"
],
"lang": {
"en-us": {
"role": {
"documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
"label": "Designated As Hedging Instrument [Member]",
"terseLabel": "Designated as Hedging Instrument"
}
}
},
"localname": "DesignatedAsHedgingInstrumentMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EMEAMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Regions of Europe, Middle East and Africa.",
"label": "E M E A [Member]",
"terseLabel": "Europe, Middle East, and Africa"
}
}
},
"localname": "EMEAMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationLongLivedAssetsByGeographicAreaDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EarningsPerShareAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share [Abstract]"
}
}
},
"localname": "EarningsPerShareAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareBasic": {
"auth_ref": [
"r59",
"r109",
"r110",
"r111",
"r112",
"r113",
"r117",
"r119",
"r126",
"r127",
"r128",
"r132",
"r133",
"r468",
"r482"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
"label": "Earnings Per Share Basic",
"terseLabel": "Basic (USD per share)"
}
}
},
"localname": "EarningsPerShareBasic",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareBasicAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share Basic [Abstract]",
"terseLabel": "Earnings per share:"
}
}
},
"localname": "EarningsPerShareBasicAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share Basic And Diluted [Abstract]",
"terseLabel": "Earnings per share:"
}
}
},
"localname": "EarningsPerShareBasicAndDilutedAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareDiluted": {
"auth_ref": [
"r59",
"r109",
"r110",
"r111",
"r112",
"r113",
"r119",
"r126",
"r127",
"r128",
"r132",
"r133",
"r468",
"r482"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
"label": "Earnings Per Share Diluted",
"terseLabel": "Diluted (USD per share)"
}
}
},
"localname": "EarningsPerShareDiluted",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareTextBlock": {
"auth_ref": [
"r129",
"r130",
"r131",
"r134"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for earnings per share.",
"label": "Earnings Per Share [Text Block]",
"terseLabel": "Earnings Per Share"
}
}
},
"localname": "EarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShare"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r417"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10040.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
"terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
}
}
},
"localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
"auth_ref": [
"r322",
"r341"
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
"label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
"terseLabel": "U.S. federal statutory rate"
}
}
},
"localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_EmployeeSeveranceMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
"label": "Employee Severance [Member]",
"terseLabel": "Employee severance and benefit costs"
}
}
},
"localname": "EmployeeSeveranceMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsLiabilitiesAssociatedWithRestructuringAndOtherCostsDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsScheduleOfRestructuringAndRelatedCostsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Equity [Abstract]"
}
}
},
"localname": "EquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r101",
"r102",
"r103",
"r106",
"r114",
"r116",
"r135",
"r195",
"r250",
"r257",
"r311",
"r312",
"r313",
"r334",
"r335",
"r418",
"r419",
"r420",
"r421",
"r422",
"r425",
"r491",
"r492",
"r493"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]",
"terseLabel": "Equity Component"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccumulatedOtherComprehensiveLossNetOfTaxesDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTaxEffectsAllocatedToEachComponentOfOtherComprehensiveLossIncomeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquitySharesOfCommonStockOutstandingDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
"auth_ref": [
"r405"
],
"lang": {
"en-us": {
"role": {
"documentation": "Measured as an estimate of fair value.",
"label": "Estimate Of Fair Value Fair Value Disclosure [Member]",
"terseLabel": "Estimate of Fair Value Measurement"
}
}
},
"localname": "EstimateOfFairValueFairValueDisclosureMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FacilityClosingMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
"label": "Facility Closing [Member]",
"terseLabel": "Facility and lease termination costs"
}
}
},
"localname": "FacilityClosingMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsScheduleOfRestructuringAndRelatedCostsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
"terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
"auth_ref": [
"r390",
"r391",
"r392",
"r401"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
"label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
"terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
"auth_ref": [
"r392"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
"label": "Fair Value Assets Level1 To Level2 Transfers Amount",
"terseLabel": "Fair value assets transferred from level 1 to level 2"
}
}
},
"localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
"auth_ref": [
"r392"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
"label": "Fair Value Assets Level2 To Level1 Transfers Amount",
"terseLabel": "Fair value assets transferred from level 2 to level 1"
}
}
},
"localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
"auth_ref": [
"r390",
"r406"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
"label": "Fair Value By Balance Sheet Grouping [Text Block]",
"terseLabel": "Schedule of Estimated Fair Value"
}
}
},
"localname": "FairValueByBalanceSheetGroupingTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueByFairValueHierarchyLevelAxis": {
"auth_ref": [
"r289",
"r290",
"r291",
"r292",
"r293",
"r294",
"r295",
"r297",
"r391",
"r446",
"r447",
"r448"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
"label": "Fair Value By Fair Value Hierarchy Level [Axis]",
"terseLabel": "Fair Value Hierarchy and NAV"
}
}
},
"localname": "FairValueByFairValueHierarchyLevelAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByMeasurementBasisAxis": {
"auth_ref": [
"r390",
"r402"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by measurement basis.",
"label": "Fair Value By Measurement Basis [Axis]",
"terseLabel": "Measurement Basis"
}
}
},
"localname": "FairValueByMeasurementBasisAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByMeasurementFrequencyAxis": {
"auth_ref": [
"r390",
"r391",
"r393",
"r394",
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by measurement frequency.",
"label": "Fair Value By Measurement Frequency [Axis]",
"terseLabel": "Measurement Frequency"
}
}
},
"localname": "FairValueByMeasurementFrequencyAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosureItemAmountsDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
"label": "Fair Value Disclosure Item Amounts [Domain]",
"terseLabel": "Fair Value Measurement"
}
}
},
"localname": "FairValueDisclosureItemAmountsDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueDisclosuresAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Disclosures [Abstract]"
}
}
},
"localname": "FairValueDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresTextBlock": {
"auth_ref": [
"r400"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
"label": "Fair Value Disclosures [Text Block]",
"terseLabel": "Fair Value Measurements"
}
}
},
"localname": "FairValueDisclosuresTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurements"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueInputsLevel1Member": {
"auth_ref": [
"r289",
"r290",
"r295",
"r297",
"r391",
"r446"
],
"lang": {
"en-us": {
"role": {
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
"label": "Fair Value Inputs Level1 [Member]",
"terseLabel": "Level 1"
}
}
},
"localname": "FairValueInputsLevel1Member",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel2Member": {
"auth_ref": [
"r289",
"r290",
"r295",
"r297",
"r391",
"r447"
],
"lang": {
"en-us": {
"role": {
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
"label": "Fair Value Inputs Level2 [Member]",
"terseLabel": "Level 2"
}
}
},
"localname": "FairValueInputsLevel2Member",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel3Member": {
"auth_ref": [
"r289",
"r290",
"r291",
"r292",
"r293",
"r294",
"r295",
"r297",
"r391",
"r448"
],
"lang": {
"en-us": {
"role": {
"documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value Inputs Level3 [Member]",
"terseLabel": "Level 3"
}
}
},
"localname": "FairValueInputsLevel3Member",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
"auth_ref": [
"r392"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
"label": "Fair Value Liabilities Level1 To Level2 Transfers Amount",
"terseLabel": "Fair value liabilities transferred from level 1 to level 2"
}
}
},
"localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
"auth_ref": [
"r392"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
"label": "Fair Value Liabilities Level2 To Level1 Transfers Amount",
"terseLabel": "Fair value liabilities transferred from level 2 to level 1"
}
}
},
"localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
"auth_ref": [
"r395",
"r401"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
"label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]",
"terseLabel": "Reconciliation of Changes in the Carrying Amount of Contingent Consideration"
}
}
},
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
"auth_ref": [
"r290",
"r389",
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Fair value measured at net asset value per share as practical expedient.",
"label": "Fair Value Measured At Net Asset Value Per Share [Member]",
"terseLabel": "Investments Measured at Net Asset Value"
}
}
},
"localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementFrequencyDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Measurement frequency.",
"label": "Fair Value Measurement Frequency [Domain]",
"terseLabel": "Measurement Frequency"
}
}
},
"localname": "FairValueMeasurementFrequencyDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
"auth_ref": [
"r398"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.",
"label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3",
"terseLabel": "Fair value liabilities transferred into level 3"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
"auth_ref": [
"r398"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
"label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3",
"terseLabel": "Fair value liabilities transferred out of level 3"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
"auth_ref": [
"r398"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
"label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3",
"terseLabel": "Fair value assets transferred into level 3"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
"auth_ref": [
"r398"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
"label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3",
"terseLabel": "Fair value assets transferred out of level 3"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
"auth_ref": [
"r396"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
"label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings",
"terseLabel": "Changes in fair value recognized in earnings"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfChangesInCarryingAmountOfContingentConsiderationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
"auth_ref": [
"r397"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases",
"terseLabel": "Additions"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfChangesInCarryingAmountOfContingentConsiderationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
"auth_ref": [
"r397"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements",
"terseLabel": "Payments"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfChangesInCarryingAmountOfContingentConsiderationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
"auth_ref": [
"r395"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value",
"periodEndLabel": "Balance at End of period",
"periodStartLabel": "Balance at Beginning of period"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfChangesInCarryingAmountOfContingentConsiderationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"auth_ref": [
"r289",
"r290",
"r291",
"r292",
"r293",
"r294",
"r295",
"r297",
"r446",
"r447",
"r448"
],
"lang": {
"en-us": {
"role": {
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
"label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
"terseLabel": "Fair Value Hierarchy and NAV"
}
}
},
"localname": "FairValueMeasurementsFairValueHierarchyDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsNonrecurringMember": {
"auth_ref": [
"r390",
"r391",
"r393",
"r394",
"r399",
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
"label": "Fair Value Measurements Nonrecurring [Member]",
"terseLabel": "Nonrecurring"
}
}
},
"localname": "FairValueMeasurementsNonrecurringMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsRecurringMember": {
"auth_ref": [
"r400",
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
"label": "Fair Value Measurements Recurring [Member]",
"terseLabel": "Recurring"
}
}
},
"localname": "FairValueMeasurementsRecurringMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
"auth_ref": [
"r375",
"r379",
"r386"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
"label": "Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]",
"terseLabel": "Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]"
}
}
},
"localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FinanceLeaseLiabilityCurrent": {
"auth_ref": [
"r435"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10200.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
"label": "Finance Lease Liability Current",
"terseLabel": "Current portion of finance lease obligations"
}
}
},
"localname": "FinanceLeaseLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseLiabilityNoncurrent": {
"auth_ref": [
"r435"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10120.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
"label": "Finance Lease Liability Noncurrent",
"terseLabel": "Finance lease long-term obligations"
}
}
},
"localname": "FinanceLeaseLiabilityNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ForeignCountryMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
"label": "Foreign Country [Member]",
"terseLabel": "Foreign Jurisdictions"
}
}
},
"localname": "ForeignCountryMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
"auth_ref": [
"r412",
"r413",
"r414",
"r416"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10230.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
"label": "Foreign Currency Transaction Gain Loss Before Tax",
"negatedLabel": "Foreign currency transaction gains"
}
}
},
"localname": "ForeignCurrencyTransactionGainLossBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ForeignCurrencyTransactionGainLossRealized": {
"auth_ref": [
"r414",
"r416"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherIncomeNetDetails": {
"order": 10010.0,
"parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.",
"label": "Foreign Currency Transaction Gain Loss Realized",
"negatedLabel": "Net realized foreign currency loss (gain)",
"terseLabel": "Foreign Currency Forward Gain, Realized"
}
}
},
"localname": "ForeignCurrencyTransactionGainLossRealized",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherIncomeNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
"auth_ref": [
"r81",
"r414",
"r416"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherIncomeNetDetails": {
"order": 10020.0,
"parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
"label": "Foreign Currency Transaction Gain Loss Unrealized",
"negatedLabel": "Net unrealized foreign currency gain"
}
}
},
"localname": "ForeignCurrencyTransactionGainLossUnrealized",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherIncomeNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ForeignExchangeForwardMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
"label": "Foreign Exchange Forward [Member]",
"terseLabel": "Foreign Exchange Forward"
}
}
},
"localname": "ForeignExchangeForwardMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_GainsLossesOnExtinguishmentOfDebt": {
"auth_ref": [
"r80",
"r244",
"r245"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10250.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
},
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": 10070.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
"label": "Gains Losses On Extinguishment Of Debt",
"negatedLabel": "Loss on extinguishment of debt"
}
}
},
"localname": "GainsLossesOnExtinguishmentOfDebt",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeographicConcentrationRiskMember": {
"auth_ref": [
"r141"
],
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
"label": "Geographic Concentration Risk [Member]",
"terseLabel": "Geographic Concentration Risk"
}
}
},
"localname": "GeographicConcentrationRiskMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_Goodwill": {
"auth_ref": [
"r200",
"r202",
"r458"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10250.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill",
"periodEndLabel": "Balance as of March 31, 2021",
"periodStartLabel": "Balance as of December 31, 2020",
"terseLabel": "Goodwill"
}
}
},
"localname": "Goodwill",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfGoodwillDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Goodwill And Intangible Assets Disclosure [Abstract]"
}
}
},
"localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
"auth_ref": [
"r205"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill Foreign Currency Translation Gain Loss",
"terseLabel": "Impact of foreign currency translation and other"
}
}
},
"localname": "GoodwillForeignCurrencyTranslationGainLoss",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfGoodwillDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
"auth_ref": [
"r203",
"r207"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill Impaired Accumulated Impairment Loss",
"terseLabel": "Accumulated impairment losses"
}
}
},
"localname": "GoodwillImpairedAccumulatedImpairmentLoss",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfGoodwillDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GoodwillImpairmentLoss": {
"auth_ref": [
"r80",
"r201",
"r204",
"r209"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill Impairment Loss",
"terseLabel": "Impairment of goodwill"
}
}
},
"localname": "GoodwillImpairmentLoss",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfGoodwillDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GoodwillLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Goodwill [Line Items]",
"terseLabel": "Goodwill [Line Items]"
}
}
},
"localname": "GoodwillLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfGoodwillDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_GoodwillPurchaseAccountingAdjustments": {
"auth_ref": [
"r206",
"r347"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill Purchase Accounting Adjustments",
"terseLabel": "Business combinations"
}
}
},
"localname": "GoodwillPurchaseAccountingAdjustments",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfGoodwillDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GoodwillRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Goodwill Roll Forward",
"terseLabel": "Goodwill [Roll Forward]"
}
}
},
"localname": "GoodwillRollForward",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfGoodwillDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_GoodwillTransfers": {
"auth_ref": [
"r206"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill Transfers",
"terseLabel": "Transfer of goodwill"
}
}
},
"localname": "GoodwillTransfers",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfGoodwillDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_HedgingDesignationAxis": {
"auth_ref": [
"r373",
"r383"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by designation of purpose of derivative instrument.",
"label": "Hedging Designation [Axis]",
"terseLabel": "Hedging Designation"
}
}
},
"localname": "HedgingDesignationAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_HedgingDesignationDomain": {
"auth_ref": [
"r373"
],
"lang": {
"en-us": {
"role": {
"documentation": "Designation of purpose of derivative instrument.",
"label": "Hedging Designation [Domain]",
"terseLabel": "Hedging Designation"
}
}
},
"localname": "HedgingDesignationDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_HedgingRelationshipDomain": {
"auth_ref": [
"r373"
],
"lang": {
"en-us": {
"role": {
"documentation": "Nature or intent of a hedge.",
"label": "Hedging Relationship [Domain]",
"terseLabel": "Hedging Relationship"
}
}
},
"localname": "HedgingRelationshipDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
"auth_ref": [
"r56",
"r159",
"r165",
"r169",
"r172",
"r175",
"r457",
"r465",
"r470",
"r483"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": 10010.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
"label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
"totalLabel": "Income before provision for income taxes",
"verboseLabel": "Income before provision for income taxes"
}
}
},
"localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Income Loss From Discontinued Operations And Disposal Of Discontinued Operations Net Of Tax Per Basic Share [Abstract]",
"terseLabel": "Numerator:"
}
}
},
"localname": "IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Income Statement [Abstract]"
}
}
},
"localname": "IncomeStatementAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationAxis": {
"auth_ref": [
"r217"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location in the income statement.",
"label": "Income Statement Location [Axis]",
"terseLabel": "Income Statement Location"
}
}
},
"localname": "IncomeStatementLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the income statement.",
"label": "Income Statement Location [Domain]",
"terseLabel": "Income Statement Location"
}
}
},
"localname": "IncomeStatementLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeTaxAuthorityAxis": {
"auth_ref": [
"r324"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by tax jurisdiction.",
"label": "Income Tax Authority [Axis]",
"terseLabel": "Income Tax Authority"
}
}
},
"localname": "IncomeTaxAuthorityAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxAuthorityDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
"label": "Income Tax Authority [Domain]",
"terseLabel": "Income Tax Authority"
}
}
},
"localname": "IncomeTaxAuthorityDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeTaxContingencyLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Income Tax Contingency [Line Items]",
"terseLabel": "Income Tax Contingency [Line Items]"
}
}
},
"localname": "IncomeTaxContingencyLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxContingencyTable": {
"auth_ref": [
"r325",
"r328",
"r330",
"r333"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
"label": "Income Tax Contingency [Table]",
"terseLabel": "Income Tax Contingency [Table]"
}
}
},
"localname": "IncomeTaxContingencyTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Income Tax Disclosure [Abstract]"
}
}
},
"localname": "IncomeTaxDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxDisclosureTextBlock": {
"auth_ref": [
"r323",
"r329",
"r331",
"r336",
"r342",
"r344",
"r345",
"r346"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
"label": "Income Tax Disclosure [Text Block]",
"terseLabel": "Income Taxes"
}
}
},
"localname": "IncomeTaxDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureIncomeTaxes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_IncomeTaxExpenseBenefit": {
"auth_ref": [
"r88",
"r115",
"r116",
"r157",
"r321",
"r337",
"r343",
"r484"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": 10020.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
"label": "Income Tax Expense Benefit",
"terseLabel": "Income tax expense"
}
}
},
"localname": "IncomeTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
"auth_ref": [
"r79"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10280.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
"label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
"terseLabel": "Accounts payable and accrued expenses"
}
}
},
"localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Increase Decrease In Other Operating Assets And Liabilities Net [Abstract]",
"terseLabel": "Changes in operating assets and liabilities, net of effect of business combinations:"
}
}
},
"localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
"auth_ref": [
"r79"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10290.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
"label": "Increase Decrease In Other Operating Capital Net",
"negatedLabel": "Other assets and liabilities"
}
}
},
"localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Increase Decrease In Stockholders Equity Roll Forward",
"terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
}
}
},
"localname": "IncreaseDecreaseInStockholdersEquityRollForward",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquitySharesOfCommonStockOutstandingDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
"auth_ref": [
"r120",
"r121",
"r122",
"r128"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails": {
"order": 10020.0,
"parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
"label": "Incremental Common Shares Attributable To Share Based Payment Arrangements",
"terseLabel": "Stock options and other awards under deferred share-based compensation programs (in shares)"
}
}
},
"localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_IntangibleAssetsNetExcludingGoodwill": {
"auth_ref": [
"r211",
"r213"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10260.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
"label": "Intangible Assets Net Excluding Goodwill",
"terseLabel": "Intangible assets, net"
}
}
},
"localname": "IntangibleAssetsNetExcludingGoodwill",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IntangibleAssetsNetIncludingGoodwill": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
"label": "Intangible Assets Net Including Goodwill",
"terseLabel": "Goodwill and identifiable intangible assets"
}
}
},
"localname": "IntangibleAssetsNetIncludingGoodwill",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestAndOtherIncome": {
"auth_ref": [
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": 10050.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
"label": "Interest And Other Income",
"terseLabel": "Interest income"
}
}
},
"localname": "InterestAndOtherIncome",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestExpense": {
"auth_ref": [
"r54",
"r153",
"r426",
"r429",
"r469"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": 10060.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
"label": "Interest Expense",
"terseLabel": "Interest expense"
}
}
},
"localname": "InterestExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestRateSwapMember": {
"auth_ref": [
"r381"
],
"lang": {
"en-us": {
"role": {
"documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
"label": "Interest Rate Swap [Member]",
"terseLabel": "Interest Rate Swap"
}
}
},
"localname": "InterestRateSwapMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_InvestmentTypeAxis": {
"auth_ref": [
"r503",
"r504",
"r505",
"r506",
"r507",
"r508",
"r509",
"r510",
"r511",
"r512",
"r513",
"r514",
"r515",
"r516",
"r517"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of investments.",
"label": "Investment Type [Axis]",
"terseLabel": "Investment Type"
}
}
},
"localname": "InvestmentTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_InvestmentTypeCategorizationMember": {
"auth_ref": [
"r503",
"r504",
"r505",
"r506",
"r507",
"r508",
"r509",
"r510",
"r511",
"r512",
"r513",
"r514",
"r515",
"r516",
"r517"
],
"lang": {
"en-us": {
"role": {
"documentation": "Asset obtained to generate income or appreciate in value.",
"label": "Investment Type Categorization [Member]",
"terseLabel": "Investments"
}
}
},
"localname": "InvestmentTypeCategorizationMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Investments Debt And Equity Securities [Abstract]"
}
}
},
"localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_LetterOfCreditMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
"label": "Letter Of Credit [Member]",
"terseLabel": "Letter of Credit"
}
}
},
"localname": "LetterOfCreditMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_Liabilities": {
"auth_ref": [
"r25",
"r87",
"r167",
"r191",
"r363",
"r366",
"r367",
"r411"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10010.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
"label": "Liabilities",
"totalLabel": "Total liabilities"
}
}
},
"localname": "Liabilities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r18",
"r87",
"r191",
"r411",
"r462",
"r477"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "Liabilities And Stockholders Equity",
"totalLabel": "Total liabilities and shareholders\u2019 equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities And Stockholders Equity [Abstract]",
"terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
}
}
},
"localname": "LiabilitiesAndStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r27",
"r87",
"r191",
"r363",
"r366",
"r367",
"r411"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10090.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "Liabilities Current",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities Current [Abstract]",
"terseLabel": "Current liabilities:"
}
}
},
"localname": "LiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesFairValueDisclosure": {
"auth_ref": [
"r390"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of financial and nonfinancial obligations.",
"label": "Liabilities Fair Value Disclosure",
"totalLabel": "Total liabilities"
}
}
},
"localname": "LiabilitiesFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesFairValueDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities Fair Value Disclosure [Abstract]",
"terseLabel": "Liabilities:"
}
}
},
"localname": "LiabilitiesFairValueDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCredit": {
"auth_ref": [
"r9",
"r461",
"r472"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
"label": "Line Of Credit",
"terseLabel": "Outstanding borrowings"
}
}
},
"localname": "LineOfCredit",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LineOfCreditFacilityCapacityAvailableForTradePurchases": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The maximum amount of borrowing capacity under a line of credit that is available as of the balance sheet date for financing purchases of goods acquired for inventory or imminent delivery to a customer.",
"label": "Line Of Credit Facility Capacity Available For Trade Purchases",
"terseLabel": "Line of credit facility, capacity available for trade purchases"
}
}
},
"localname": "LineOfCreditFacilityCapacityAvailableForTradePurchases",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LineOfCreditFacilityDecreaseForgiveness1": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of decrease in line of credit facility from forgiveness by the holder of the line of credit.",
"label": "Line Of Credit Facility Decrease Forgiveness1",
"terseLabel": "Line of credit facility, decrease, forgiveness"
}
}
},
"localname": "LineOfCreditFacilityDecreaseForgiveness1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
"auth_ref": [
"r24"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
"label": "Line Of Credit Facility Maximum Borrowing Capacity",
"terseLabel": "Maximum borrowing capacity under accounts receivable financing agreement"
}
}
},
"localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
"auth_ref": [
"r24"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
"label": "Line Of Credit Facility Remaining Borrowing Capacity",
"terseLabel": "Remaining capacity available under accounts receivable financing agreement"
}
}
},
"localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LitigationStatusAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by status of pending, threatened, or settled litigation.",
"label": "Litigation Status [Axis]",
"terseLabel": "Litigation Status"
}
}
},
"localname": "LitigationStatusAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LitigationStatusDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Status of pending, threatened, or settled litigation.",
"label": "Litigation Status [Domain]",
"terseLabel": "Litigation Status"
}
}
},
"localname": "LitigationStatusDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
"auth_ref": [
"r182"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
"label": "Long Lived Assets By Geographic Areas Table [Text Block]",
"terseLabel": "Long-Lived Assets by Geographic Area"
}
}
},
"localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LongTermDebt": {
"auth_ref": [
"r9",
"r243",
"r461",
"r474"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
"label": "Long Term Debt",
"terseLabel": "Long-term debt",
"totalLabel": "Total"
}
}
},
"localname": "LongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtByMaturityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Long Term Debt By Maturity [Abstract]",
"terseLabel": "Principal"
}
}
},
"localname": "LongTermDebtByMaturityAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LongTermDebtFairValue": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
"label": "Long Term Debt Fair Value",
"terseLabel": "Long-term debt, fair value"
}
}
},
"localname": "LongTermDebtFairValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
"auth_ref": [
"r93",
"r240"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails": {
"order": 10050.0,
"parentTag": "us-gaap_LongTermDebt",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long Term Debt Maturities Repayments Of Principal After Year Five",
"terseLabel": "2026 and thereafter"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
"auth_ref": [
"r93",
"r240"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails": {
"order": 10040.0,
"parentTag": "us-gaap_LongTermDebt",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long Term Debt Maturities Repayments Of Principal In Year Five",
"terseLabel": "2025"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
"auth_ref": [
"r93",
"r240"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails": {
"order": 10030.0,
"parentTag": "us-gaap_LongTermDebt",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long Term Debt Maturities Repayments Of Principal In Year Four",
"terseLabel": "2024"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
"auth_ref": [
"r93",
"r240"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails": {
"order": 10020.0,
"parentTag": "us-gaap_LongTermDebt",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long Term Debt Maturities Repayments Of Principal In Year Three",
"terseLabel": "2023"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
"auth_ref": [
"r93",
"r240"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails": {
"order": 10010.0,
"parentTag": "us-gaap_LongTermDebt",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long Term Debt Maturities Repayments Of Principal In Year Two",
"terseLabel": "2022"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
"auth_ref": [
"r93"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
"label": "Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year",
"terseLabel": "Remainder of 2021"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsContractualMaturitiesOfDebtObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtNoncurrent": {
"auth_ref": [
"r28"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10100.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
"label": "Long Term Debt Noncurrent",
"terseLabel": "Long-term debt",
"totalLabel": "Total debt obligations, non-current portion"
}
}
},
"localname": "LongTermDebtNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongtermDebtTypeAxis": {
"auth_ref": [
"r28"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of long-term debt.",
"label": "Longterm Debt Type [Axis]",
"terseLabel": "Long-term Debt, Type"
}
}
},
"localname": "LongtermDebtTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LongtermDebtTypeDomain": {
"auth_ref": [
"r28",
"r241"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Longterm Debt Type [Domain]",
"terseLabel": "Long-term Debt, Type"
}
}
},
"localname": "LongtermDebtTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_LossContingenciesLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Loss Contingencies [Line Items]",
"terseLabel": "Loss Contingencies [Line Items]"
}
}
},
"localname": "LossContingenciesLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LossContingenciesTable": {
"auth_ref": [
"r230",
"r231",
"r232",
"r233",
"r234",
"r235",
"r236",
"r238",
"r239"
],
"lang": {
"en-us": {
"role": {
"documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
"label": "Loss Contingencies [Table]",
"terseLabel": "Loss Contingencies [Table]"
}
}
},
"localname": "LossContingenciesTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LossContingencyNumberOfPlaintiffs": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
"label": "Loss Contingency Number Of Plaintiffs",
"terseLabel": "Number of plaintiffs"
}
}
},
"localname": "LossContingencyNumberOfPlaintiffs",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
],
"xbrltype": "integerItemType"
},
"us-gaap_MinorityInterestOwnershipPercentageByParent": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
"label": "Minority Interest Ownership Percentage By Parent",
"terseLabel": "Minority interest ownership percentage"
}
}
},
"localname": "MinorityInterestOwnershipPercentageByParent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r77"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10030.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "Net Cash Provided By Used In Financing Activities",
"totalLabel": "Net cash (used in) provided by financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided By Used In Financing Activities [Abstract]",
"terseLabel": "Cash flows from financing activities:"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r77"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10020.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "Net Cash Provided By Used In Investing Activities",
"totalLabel": "Net cash used in investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided By Used In Investing Activities [Abstract]",
"terseLabel": "Cash flows from investing activities:"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r77",
"r78",
"r81"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10010.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "Net Cash Provided By Used In Operating Activities",
"totalLabel": "Net cash provided by (used in) operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided By Used In Operating Activities [Abstract]",
"terseLabel": "Cash flows from operating activities:"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetIncomeLoss": {
"auth_ref": [
"r2",
"r47",
"r50",
"r57",
"r81",
"r87",
"r105",
"r109",
"r110",
"r111",
"r112",
"r115",
"r116",
"r125",
"r159",
"r165",
"r169",
"r172",
"r175",
"r191",
"r411",
"r466",
"r480"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10180.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": {
"order": 10010.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
},
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
"label": "Net Income Loss",
"terseLabel": "Net income",
"totalLabel": "Net income",
"verboseLabel": "Net income"
}
}
},
"localname": "NetIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NonoperatingIncomeExpense": {
"auth_ref": [
"r65"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": 10040.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
"label": "Nonoperating Income Expense",
"negatedTotalLabel": "Total other expense, net"
}
}
},
"localname": "NonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NumberOfReportableSegments": {
"auth_ref": [
"r147"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
"label": "Number Of Reportable Segments",
"terseLabel": "Number of reportable segments"
}
}
},
"localname": "NumberOfReportableSegments",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBasisOfPresentationAndChangesInSignificantAccountingPoliciesNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "integerItemType"
},
"us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
"auth_ref": [
"r44"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.",
"label": "Oci Before Reclassifications Before Tax Attributable To Parent",
"terseLabel": "Unrealized gain (loss) during period, before taxes"
}
}
},
"localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTaxEffectsAllocatedToEachComponentOfOtherComprehensiveLossIncomeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
"auth_ref": [
"r44",
"r53"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.",
"label": "Oci Before Reclassifications Net Of Tax Attributable To Parent",
"terseLabel": "Other comprehensive loss before reclassifications",
"verboseLabel": "Unrealized gain (loss) during period, net of taxes"
}
}
},
"localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccumulatedOtherComprehensiveLossNetOfTaxesDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTaxEffectsAllocatedToEachComponentOfOtherComprehensiveLossIncomeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingCostsAndExpensesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Operating Costs And Expenses [Abstract]",
"terseLabel": "Costs and operating expenses:"
}
}
},
"localname": "OperatingCostsAndExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
"r159",
"r165",
"r169",
"r172",
"r175"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": 10030.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "Operating Income Loss",
"terseLabel": "Operating income (loss)",
"totalLabel": "Income from operations"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityCurrent": {
"auth_ref": [
"r435"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10190.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
"label": "Operating Lease Liability Current",
"terseLabel": "Current portion of operating lease obligations"
}
}
},
"localname": "OperatingLeaseLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityNoncurrent": {
"auth_ref": [
"r435"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10110.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
"label": "Operating Lease Liability Noncurrent",
"terseLabel": "Operating lease long-term obligations"
}
}
},
"localname": "OperatingLeaseLiabilityNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseRightOfUseAsset": {
"auth_ref": [
"r434"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10240.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's right to use underlying asset under operating lease.",
"label": "Operating Lease Right Of Use Asset",
"terseLabel": "Operating lease right-of-use assets"
}
}
},
"localname": "OperatingLeaseRightOfUseAsset",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingSegmentsMember": {
"auth_ref": [
"r164",
"r165",
"r166",
"r167",
"r169",
"r175"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
"label": "Operating Segments [Member]",
"terseLabel": "Operating Segments"
}
}
},
"localname": "OperatingSegmentsMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_OtherAssetsNoncurrent": {
"auth_ref": [
"r22"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10280.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncurrent assets classified as other.",
"label": "Other Assets Noncurrent",
"terseLabel": "Other long-term assets"
}
}
},
"localname": "OtherAssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
"auth_ref": [
"r360",
"r361",
"r364"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": {
"order": 10030.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
"label": "Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent",
"terseLabel": "Foreign currency translation adjustments, net of income tax benefit of $708 and $0, respectively",
"verboseLabel": "Foreign currency translation adjustment, net of taxes"
}
}
},
"localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
"auth_ref": [
"r42"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).",
"label": "Other Comprehensive Income Loss Before Reclassifications Tax",
"negatedLabel": "Income tax benefit",
"terseLabel": "Foreign currency translation adjustment, before taxes"
}
}
},
"localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTaxEffectsAllocatedToEachComponentOfOtherComprehensiveLossIncomeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
"auth_ref": [
"r39",
"r41"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
"label": "Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax",
"verboseLabel": "Unrealized gain (loss) on derivative instruments, net of taxes"
}
}
},
"localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
"auth_ref": [
"r42"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
"label": "Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax",
"negatedLabel": "Income tax benefit related to unrealized gain (loss) on derivative instruments recorded in other comprehensive loss"
}
}
},
"localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnauditedParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
"auth_ref": [
"r37",
"r42",
"r415",
"r424"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
"label": "Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax",
"negatedLabel": "Other comprehensive income (loss), foreign currency translation adjustment, tax",
"terseLabel": "Income tax benefit"
}
}
},
"localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTaxEffectsAllocatedToEachComponentOfOtherComprehensiveLossIncomeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnauditedParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
"auth_ref": [
"r48",
"r51",
"r360",
"r361",
"r364"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
"label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent",
"terseLabel": "Total other comprehensive income (loss), net of taxes"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTaxEffectsAllocatedToEachComponentOfOtherComprehensiveLossIncomeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherIncomeAndExpensesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Other Income And Expenses [Abstract]",
"terseLabel": "Total other expense, net:",
"verboseLabel": "Other (income) expense, net:"
}
}
},
"localname": "OtherIncomeAndExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherIncomeNetDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_OtherLiabilitiesNoncurrent": {
"auth_ref": [
"r29"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10150.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
"label": "Other Liabilities Noncurrent",
"terseLabel": "Other long-term liabilities"
}
}
},
"localname": "OtherLiabilitiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNoncashIncomeExpense": {
"auth_ref": [
"r81"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10260.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
"label": "Other Noncash Income Expense",
"negatedLabel": "Other non-cash items"
}
}
},
"localname": "OtherNoncashIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNoncurrentLiabilitiesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
"label": "Other Noncurrent Liabilities [Member]",
"terseLabel": "Other long-term liabilities"
}
}
},
"localname": "OtherNoncurrentLiabilitiesMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesInterestRateSwapsDesignatedAsHedgingInstrumentsOnConsolidatedBalanceSheetsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"auth_ref": [
"r66"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherIncomeNetDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": 10080.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
"label": "Other Nonoperating Income Expense",
"negatedLabel": "Other income, net",
"negatedTotalLabel": "Total other income, net"
}
}
},
"localname": "OtherNonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherIncomeNetDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherRestructuringMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Restructuring and related activities classified as other.",
"label": "Other Restructuring [Member]",
"verboseLabel": "Other costs"
}
}
},
"localname": "OtherRestructuringMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsLiabilitiesAssociatedWithRestructuringAndOtherCostsDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsScheduleOfRestructuringAndRelatedCostsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
"auth_ref": [
"r76"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10100.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
"label": "Payment For Contingent Consideration Liability Financing Activities",
"negatedLabel": "Payments of contingent consideration related to business combinations"
}
}
},
"localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsForRepurchaseOfCommonStock": {
"auth_ref": [
"r73"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10120.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow to reacquire common stock during the period.",
"label": "Payments For Repurchase Of Common Stock",
"negatedLabel": "Payments for repurchases of common stock"
}
}
},
"localname": "PaymentsForRepurchaseOfCommonStock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsOfDebtIssuanceCosts": {
"auth_ref": [
"r75"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10050.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
"label": "Payments Of Debt Issuance Costs",
"negatedLabel": "Payments of debt financing costs"
}
}
},
"localname": "PaymentsOfDebtIssuanceCosts",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
"auth_ref": [
"r73"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10140.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
"label": "Payments Related To Tax Withholding For Share Based Compensation",
"negatedLabel": "Payments related to tax withholdings for share-based compensation"
}
}
},
"localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
"auth_ref": [
"r69"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10150.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
"label": "Payments To Acquire Businesses Net Of Cash Acquired",
"negatedLabel": "Payments related to acquisition of business, net of cash acquired",
"terseLabel": "Bussiness acquisition payment of cash"
}
}
},
"localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
"auth_ref": [
"r70"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10160.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
"label": "Payments To Acquire Property Plant And Equipment",
"negatedLabel": "Purchases of property and equipment"
}
}
},
"localname": "PaymentsToAcquirePropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PendingLitigationMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
"label": "Pending Litigation [Member]",
"terseLabel": "Pending Litigation"
}
}
},
"localname": "PendingLitigationMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PortionAtFairValueFairValueDisclosureMember": {
"auth_ref": [
"r404"
],
"lang": {
"en-us": {
"role": {
"documentation": "Measured at fair value for financial reporting purposes.",
"label": "Portion At Fair Value Fair Value Disclosure [Member]",
"terseLabel": "Fair Value Disclosure Item Amounts [Default]"
}
}
},
"localname": "PortionAtFairValueFairValueDisclosureMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PreferredStockParOrStatedValuePerShare": {
"auth_ref": [
"r11"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
"label": "Preferred Stock Par Or Stated Value Per Share",
"terseLabel": "Preferred stock par value (USD per share)"
}
}
},
"localname": "PreferredStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_PreferredStockSharesAuthorized": {
"auth_ref": [
"r11"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
"label": "Preferred Stock Shares Authorized",
"terseLabel": "Preferred stock shares authorized (in shares)"
}
}
},
"localname": "PreferredStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesIssued": {
"auth_ref": [
"r11"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
"label": "Preferred Stock Shares Issued",
"terseLabel": "Preferred stock shares issued (in shares)"
}
}
},
"localname": "PreferredStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesOutstanding": {
"auth_ref": [
"r11"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
"label": "Preferred Stock Shares Outstanding",
"terseLabel": "Preferred stock shares outstanding (in shares)"
}
}
},
"localname": "PreferredStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockValue": {
"auth_ref": [
"r11"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10040.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Preferred Stock Value",
"terseLabel": "Preferred stock, $0.01 par value; 30,000 shares authorized, 0 shares issued and outstanding at March 31, 2021 and December 31, 2020"
}
}
},
"localname": "PreferredStockValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
"auth_ref": [
"r3",
"r20",
"r21"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10310.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
"label": "Prepaid Expense And Other Assets Current",
"terseLabel": "Prepaid expenses and other current assets"
}
}
},
"localname": "PrepaidExpenseAndOtherAssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
"auth_ref": [
"r0"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
"label": "Prior Period Reclassification Adjustment Description",
"terseLabel": "Reclassification"
}
}
},
"localname": "PriorPeriodReclassificationAdjustmentDescription",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBasisOfPresentationAndChangesInSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ProceedsFromAccountsReceivableSecuritization": {
"auth_ref": [
"r72"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10070.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Proceeds from securitizations of receivables treated as collateralized borrowings, which are classified as financing transactions.",
"label": "Proceeds From Accounts Receivable Securitization",
"terseLabel": "Proceeds from accounts receivable financing agreement"
}
}
},
"localname": "ProceedsFromAccountsReceivableSecuritization",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromLinesOfCredit": {
"auth_ref": [
"r72",
"r91"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10090.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
"label": "Proceeds From Lines Of Credit",
"terseLabel": "Proceeds from revolving line of credit"
}
}
},
"localname": "ProceedsFromLinesOfCredit",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromSaleAndCollectionOfReceivables": {
"auth_ref": [
"r68"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow associated with the proceeds from sale and collection of receivables during the period.",
"label": "Proceeds From Sale And Collection Of Receivables",
"terseLabel": "Proceeds from sale of trade receivables"
}
}
},
"localname": "ProceedsFromSaleAndCollectionOfReceivables",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromStockOptionsExercised": {
"auth_ref": [
"r71",
"r306"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10130.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
"label": "Proceeds From Stock Options Exercised",
"terseLabel": "Proceeds from exercises of stock options"
}
}
},
"localname": "ProceedsFromStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentNet": {
"auth_ref": [
"r5",
"r6",
"r216",
"r478"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10230.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property Plant And Equipment Net",
"terseLabel": "Property and equipment, net",
"verboseLabel": "Total property and equipment, net"
}
}
},
"localname": "PropertyPlantAndEquipmentNet",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationLongLivedAssetsByGeographicAreaDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProvisionForDoubtfulAccounts": {
"auth_ref": [
"r60",
"r199"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10210.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
"label": "Provision For Doubtful Accounts",
"terseLabel": "(Recovery from) provision for doubtful accounts"
}
}
},
"localname": "ProvisionForDoubtfulAccounts",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ReceivablesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Receivables [Abstract]"
}
}
},
"localname": "ReceivablesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
"auth_ref": [
"r44"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
"label": "Reclassification From Aoci Current Period Before Tax Attributable To Parent",
"negatedLabel": "Reclassification adjustment, before taxes"
}
}
},
"localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTaxEffectsAllocatedToEachComponentOfOtherComprehensiveLossIncomeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
"auth_ref": [
"r44",
"r53"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
"label": "Reclassification From Aoci Current Period Net Of Tax Attributable To Parent",
"negatedLabel": "Reclassification adjustments",
"negatedTerseLabel": "Reclassification adjustment, net of taxes"
}
}
},
"localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccumulatedOtherComprehensiveLossNetOfTaxesDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTaxEffectsAllocatedToEachComponentOfOtherComprehensiveLossIncomeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ReclassificationFromAociCurrentPeriodTax": {
"auth_ref": [
"r42",
"r45"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).",
"label": "Reclassification From Aoci Current Period Tax",
"terseLabel": "Income tax expense"
}
}
},
"localname": "ReclassificationFromAociCurrentPeriodTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTaxEffectsAllocatedToEachComponentOfOtherComprehensiveLossIncomeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
"label": "Reclassification Out Of Accumulated Other Comprehensive Income Table [Text Block]",
"terseLabel": "Reclassification out of Accumulated Other Comprehensive (Loss) Income"
}
}
},
"localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RelatedPartyTransactionLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Related Party Transaction [Line Items]",
"terseLabel": "Related Party Transaction [Line Items]"
}
}
},
"localname": "RelatedPartyTransactionLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
"label": "Related Party Transaction Purchases From Related Party",
"terseLabel": "Receivables from related party"
}
}
},
"localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RelatedPartyTransactionsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Related Party Transactions [Abstract]"
}
}
},
"localname": "RelatedPartyTransactionsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
"auth_ref": [
"r436",
"r437",
"r439",
"r443",
"r444"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
"label": "Related Party Transactions Disclosure [Text Block]",
"terseLabel": "Related-Party Transactions"
}
}
},
"localname": "RelatedPartyTransactionsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactions"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RepaymentsOfAccountsReceivableSecuritization": {
"auth_ref": [
"r74"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10080.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Repayments of securitizations of receivables treated as collateralized borrowings, which are classified as financing transactions.",
"label": "Repayments Of Accounts Receivable Securitization",
"negatedLabel": "Repayments of accounts receivable financing agreement"
}
}
},
"localname": "RepaymentsOfAccountsReceivableSecuritization",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
"auth_ref": [
"r74"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10110.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
"label": "Repayments Of Long Term Capital Lease Obligations",
"negatedLabel": "Payments of finance leases"
}
}
},
"localname": "RepaymentsOfLongTermCapitalLeaseObligations",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RepaymentsOfLongTermDebt": {
"auth_ref": [
"r74"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10060.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
"label": "Repayments Of Long Term Debt",
"negatedLabel": "Repayments of long-term debt",
"terseLabel": "Repayments of Long-term debt"
}
}
},
"localname": "RepaymentsOfLongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestructuringAndRelatedActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Restructuring And Related Activities [Abstract]"
}
}
},
"localname": "RestructuringAndRelatedActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
"auth_ref": [
"r226"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
"label": "Restructuring And Related Activities Disclosure [Text Block]",
"terseLabel": "Restructuring and Other Costs"
}
}
},
"localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCosts"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RestructuringAndRelatedCostIncurredCost": {
"auth_ref": [
"r219",
"r220",
"r224",
"r225"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
"label": "Restructuring And Related Cost Incurred Cost",
"terseLabel": "Total restructuring and other costs"
}
}
},
"localname": "RestructuringAndRelatedCostIncurredCost",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsScheduleOfRestructuringAndRelatedCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestructuringCostAndReserveAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of restructuring cost.",
"label": "Restructuring Cost And Reserve [Axis]",
"terseLabel": "Restructuring Type"
}
}
},
"localname": "RestructuringCostAndReserveAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsLiabilitiesAssociatedWithRestructuringAndOtherCostsDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsScheduleOfRestructuringAndRelatedCostsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RestructuringCostAndReserveLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Restructuring Cost And Reserve [Line Items]",
"terseLabel": "Restructuring Cost And Reserve [Line Items]"
}
}
},
"localname": "RestructuringCostAndReserveLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsLiabilitiesAssociatedWithRestructuringAndOtherCostsDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsScheduleOfRestructuringAndRelatedCostsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RestructuringReserveRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Restructuring Reserve Roll Forward",
"terseLabel": "Restructuring Reserve"
}
}
},
"localname": "RestructuringReserveRollForward",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsLiabilitiesAssociatedWithRestructuringAndOtherCostsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r14",
"r257",
"r314",
"r476",
"r495",
"r500"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10080.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings Accumulated Deficit",
"terseLabel": "Accumulated deficit"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r101",
"r102",
"r103",
"r106",
"r114",
"r116",
"r195",
"r311",
"r312",
"r313",
"r334",
"r335",
"r491",
"r493"
],
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings [Member]",
"terseLabel": "Accumulated Deficit"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromContractWithCustomerAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Revenue From Contract With Customer [Abstract]"
}
}
},
"localname": "RevenueFromContractWithCustomerAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
"auth_ref": [
"r150",
"r151",
"r164",
"r170",
"r171",
"r178",
"r179",
"r184",
"r281",
"r282",
"r456"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": 10090.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
"label": "Revenue From Contract With Customer Excluding Assessed Tax",
"terseLabel": "Revenue"
}
}
},
"localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
"auth_ref": [
"r84",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r287"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for revenue from contract with customer.",
"label": "Revenue From Contract With Customer Policy [Text Block]",
"terseLabel": "Revenue from Contracts with Customers"
}
}
},
"localname": "RevenueFromContractWithCustomerPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBasisOfPresentationAndChangesInSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RevenueFromContractWithCustomerTextBlock": {
"auth_ref": [
"r263",
"r264",
"r265",
"r266",
"r267",
"r268",
"r271",
"r272",
"r285",
"r287"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
"label": "Revenue From Contract With Customer [Text Block]",
"terseLabel": "Revenue from Contract with Customers"
}
}
},
"localname": "RevenueFromContractWithCustomerTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRevenueFromContractsWithCustomers"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
"auth_ref": [
"r181"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
"label": "Revenue From External Customers By Geographic Areas Table [Text Block]",
"terseLabel": "Total Revenue by Geographic Area"
}
}
},
"localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RevenueFromRelatedParties": {
"auth_ref": [
"r62",
"r502"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
"label": "Revenue From Related Parties",
"verboseLabel": "Revenue from related parties"
}
}
},
"localname": "RevenueFromRelatedParties",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RevenueRemainingPerformanceObligation": {
"auth_ref": [
"r270"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
"label": "Revenue Remaining Performance Obligation",
"terseLabel": "Unsatisfied performance obligations under contracts with a contract term greater than one year"
}
}
},
"localname": "RevenueRemainingPerformanceObligation",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]",
"verboseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]"
}
}
},
"localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
"label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]",
"terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]"
}
}
},
"localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Revenues From External Customers And Long Lived Assets [Line Items]",
"terseLabel": "Revenues by Geographic Location",
"verboseLabel": "Long-Lived Assets by Geographic Location"
}
}
},
"localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationLongLivedAssetsByGeographicAreaDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RevolvingCreditFacilityMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
"label": "Revolving Credit Facility [Member]",
"terseLabel": "Revolving credit facility due August 2024"
}
}
},
"localname": "RevolvingCreditFacilityMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RisksAndUncertaintiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Risks And Uncertainties [Abstract]"
}
}
},
"localname": "RisksAndUncertaintiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_SalesRevenueNetMember": {
"auth_ref": [
"r142",
"r184"
],
"lang": {
"en-us": {
"role": {
"documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
"label": "Sales Revenue Net [Member]",
"terseLabel": "Net Service Revenue"
}
}
},
"localname": "SalesRevenueNetMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureConcentrationOfCreditRiskNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
"auth_ref": [
"r33"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
"label": "Schedule Of Accounts Notes Loans And Financing Receivable [Text Block]",
"terseLabel": "Schedule of Billed Accounts Receivable, Net"
}
}
},
"localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
"auth_ref": [
"r44",
"r423",
"r425"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
"label": "Schedule Of Accumulated Other Comprehensive Income Loss Table [Text Block]",
"terseLabel": "Schedule of Accumulated Other Comprehensive Loss, Net of Tax"
}
}
},
"localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
"auth_ref": [
"r349",
"r350"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
"label": "Schedule Of Business Acquisitions By Acquisition [Table]",
"terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]"
}
}
},
"localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureBusinessCombinationsNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
"auth_ref": [
"r28",
"r90",
"r251",
"r254",
"r255",
"r256",
"r427",
"r428",
"r431",
"r471"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
"label": "Schedule Of Debt Instruments [Text Block]",
"terseLabel": "Schedule of Debt Obligations"
}
}
},
"localname": "ScheduleOfDebtInstrumentsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
"auth_ref": [
"r379"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
"label": "Schedule Of Derivative Instruments In Statement Of Financial Position Fair Value [Text Block]",
"terseLabel": "Interest Rate Swaps Designated as Hedging Instruments on Consolidated Balance Sheets"
}
}
},
"localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureDerivativesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
"auth_ref": [
"r128"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
"label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
"terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
}
}
},
"localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
"auth_ref": [
"r390",
"r391"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
"label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
"terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis"
}
}
},
"localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfGoodwillTable": {
"auth_ref": [
"r208",
"r210"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
"label": "Schedule Of Goodwill [Table]",
"terseLabel": "Schedule Of Goodwill [Table]"
}
}
},
"localname": "ScheduleOfGoodwillTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfGoodwillDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfGoodwillTextBlock": {
"auth_ref": [
"r208",
"r210"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
"label": "Schedule Of Goodwill [Text Block]",
"terseLabel": "Schedule of Goodwill"
}
}
},
"localname": "ScheduleOfGoodwillTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
"auth_ref": [
"r240"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
"label": "Schedule Of Maturities Of Long Term Debt Table [Text Block]",
"terseLabel": "Contractual Maturities of Debt Obligations"
}
}
},
"localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
"label": "Schedule Of Other Nonoperating Income Expense Table [Text Block]",
"terseLabel": "Schedule of Other Income, Net (Details)"
}
}
},
"localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
"auth_ref": [
"r89",
"r440",
"r442"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
"label": "Schedule Of Related Party Transactions By Related Party [Table]",
"terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
}
}
},
"localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfRepurchaseAgreements": {
"auth_ref": [
"r92"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for repurchase agreements.",
"label": "Schedule Of Repurchase Agreements",
"terseLabel": "Schedule of Repurchase Activity"
}
}
},
"localname": "ScheduleOfRepurchaseAgreements",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
"auth_ref": [
"r221",
"r222",
"r223"
],
"lang": {
"en-us": {
"role": {
"documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
"label": "Schedule Of Restructuring And Related Costs [Table]",
"terseLabel": "Schedule Of Restructuring And Related Costs [Table]"
}
}
},
"localname": "ScheduleOfRestructuringAndRelatedCostsTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsLiabilitiesAssociatedWithRestructuringAndOtherCostsDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsScheduleOfRestructuringAndRelatedCostsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
"auth_ref": [
"r221",
"r222",
"r223"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
"label": "Schedule Of Restructuring And Related Costs [Text Block]",
"terseLabel": "Schedule of Restructuring and Related Costs"
}
}
},
"localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
"auth_ref": [
"r55",
"r183"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
"label": "Schedule Of Revenues From External Customers And Long Lived Assets [Table]",
"terseLabel": "Schedule Of Revenues From External Customers And Long Lived Assets [Table]"
}
}
},
"localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationLongLivedAssetsByGeographicAreaDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureOperationsByGeographicLocationTotalRevenueByGeographicAreaDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
"auth_ref": [
"r159",
"r162",
"r168",
"r208"
],
"lang": {
"en-us": {
"role": {
"documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
"label": "Schedule Of Segment Reporting Information By Segment [Table]",
"terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]"
}
}
},
"localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
"auth_ref": [
"r159",
"r162",
"r168",
"r208"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
"label": "Schedule Of Segment Reporting Information By Segment [Text Block]",
"terseLabel": "Schedule of Segment Information"
}
}
},
"localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfStockByClassTable": {
"auth_ref": [
"r31",
"r85",
"r136",
"r137",
"r247",
"r248",
"r249",
"r251",
"r252",
"r253",
"r254",
"r255",
"r256",
"r257"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
"label": "Schedule Of Stock By Class [Table]",
"terseLabel": "Schedule Of Stock By Class [Table]"
}
}
},
"localname": "ScheduleOfStockByClassTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityRepurchaseActivityDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquitySharesOfCommonStockOutstandingDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
"auth_ref": [
"r250"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
"label": "Schedule Of Stockholders Equity Table [Text Block]",
"terseLabel": "Shares of Common Stock Outstanding"
}
}
},
"localname": "ScheduleOfStockholdersEquityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SecuredDebtMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
"label": "Secured Debt [Member]",
"terseLabel": "Secured Debt"
}
}
},
"localname": "SecuredDebtMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SegmentDomain": {
"auth_ref": [
"r146",
"r150",
"r151",
"r152",
"r153",
"r154",
"r155",
"r156",
"r157",
"r158",
"r159",
"r160",
"r161",
"r164",
"r165",
"r166",
"r167",
"r169",
"r170",
"r171",
"r172",
"r173",
"r175",
"r184",
"r485"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
"label": "Segment [Domain]",
"terseLabel": "Segments"
}
}
},
"localname": "SegmentDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfGoodwillDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SegmentReportingAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Segment Reporting [Abstract]"
}
}
},
"localname": "SegmentReportingAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_SegmentReportingDisclosureTextBlock": {
"auth_ref": [
"r146",
"r148",
"r149",
"r159",
"r163",
"r169",
"r173",
"r174",
"r175",
"r176",
"r178",
"r183",
"r184",
"r185"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
"label": "Segment Reporting Disclosure [Text Block]",
"terseLabel": "Segment Information"
}
}
},
"localname": "SegmentReportingDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SegmentReportingInformationLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Segment Reporting Information [Line Items]",
"terseLabel": "Segment Reporting Information [Line Items]"
}
}
},
"localname": "SegmentReportingInformationLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SegmentsGeographicalAreasAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Segments Geographical Areas [Abstract]"
}
}
},
"localname": "SegmentsGeographicalAreasAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_SellingGeneralAndAdministrativeExpense": {
"auth_ref": [
"r64"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
"order": 10120.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
"label": "Selling General And Administrative Expense",
"terseLabel": "Selling, general, and administrative expenses"
}
}
},
"localname": "SellingGeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
"label": "Selling General And Administrative Expenses [Member]",
"terseLabel": "Selling, general, and administrative expenses"
}
}
},
"localname": "SellingGeneralAndAdministrativeExpensesMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensation": {
"auth_ref": [
"r79"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"order": 10200.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncash expense for share-based payment arrangement.",
"label": "Share Based Compensation",
"terseLabel": "Share-based compensation"
}
}
},
"localname": "ShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SharesOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
"label": "Shares Outstanding",
"periodEndLabel": "Common stock shares, ending balance",
"periodStartLabel": "Common stock shares, beginning balance"
}
}
},
"localname": "SharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquitySharesOfCommonStockOutstandingDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StatementBusinessSegmentsAxis": {
"auth_ref": [
"r1",
"r146",
"r150",
"r151",
"r152",
"r153",
"r154",
"r155",
"r156",
"r157",
"r158",
"r159",
"r160",
"r161",
"r164",
"r165",
"r166",
"r167",
"r169",
"r170",
"r171",
"r172",
"r173",
"r175",
"r184",
"r208",
"r218",
"r220",
"r225",
"r485"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by business segments.",
"label": "Statement Business Segments [Axis]",
"terseLabel": "Segments"
}
}
},
"localname": "StatementBusinessSegmentsAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsScheduleOfGoodwillDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureSegmentInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementClassOfStockAxis": {
"auth_ref": [
"r10",
"r11",
"r12",
"r85",
"r87",
"r119",
"r123",
"r124",
"r126",
"r128",
"r136",
"r137",
"r138",
"r191",
"r250",
"r411"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by the different classes of stock of the entity.",
"label": "Statement Class Of Stock [Axis]",
"terseLabel": "Class of Stock"
}
}
},
"localname": "StatementClassOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityRepurchaseActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r32",
"r101",
"r102",
"r103",
"r106",
"r114",
"r116",
"r135",
"r195",
"r250",
"r257",
"r311",
"r312",
"r313",
"r334",
"r335",
"r418",
"r419",
"r420",
"r421",
"r422",
"r425",
"r491",
"r492",
"r493"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by component of equity.",
"label": "Statement Equity Components [Axis]",
"terseLabel": "Equity Components"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccumulatedOtherComprehensiveLossNetOfTaxesDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTaxEffectsAllocatedToEachComponentOfOtherComprehensiveLossIncomeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquitySharesOfCommonStockOutstandingDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Statement [Line Items]",
"terseLabel": "Statement [Line Items]"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement Of Cash Flows [Abstract]"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement Of Financial Position [Abstract]"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement Of Income And Comprehensive Income [Abstract]"
}
}
},
"localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement Of Stockholders Equity [Abstract]"
}
}
},
"localname": "StatementOfStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
"r101",
"r102",
"r103",
"r135",
"r456"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]",
"terseLabel": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesOther": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of stock issued attributable to transactions classified as other.",
"label": "Stock Issued During Period Shares Other",
"terseLabel": "Issuances of common stock"
}
}
},
"localname": "StockIssuedDuringPeriodSharesOther",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquitySharesOfCommonStockOutstandingDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueNewIssues": {
"auth_ref": [
"r11",
"r12",
"r250",
"r257"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
"label": "Stock Issued During Period Value New Issues",
"terseLabel": "Issuances of common stock"
}
}
},
"localname": "StockIssuedDuringPeriodValueNewIssues",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of stock repurchase plan authorized.",
"label": "Stock Repurchase Program Authorized Amount1",
"terseLabel": "Stock Repurchase Program 2021, Authorized Amount"
}
}
},
"localname": "StockRepurchaseProgramAuthorizedAmount1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount remaining of a stock repurchase plan authorized.",
"label": "Stock Repurchase Program Remaining Authorized Repurchase Amount1",
"terseLabel": "Stock repurchase program, remaining authorization to repurchase"
}
}
},
"localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockRepurchasedDuringPeriodShares": {
"auth_ref": [
"r11",
"r12",
"r250",
"r257"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
"label": "Stock Repurchased During Period Shares",
"negatedLabel": "Repurchases of common stock",
"terseLabel": "Stock repurchased during period, shares",
"verboseLabel": "Stock repurchased (in shares)"
}
}
},
"localname": "StockRepurchasedDuringPeriodShares",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityRepurchaseActivityDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquitySharesOfCommonStockOutstandingDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockRepurchasedDuringPeriodValue": {
"auth_ref": [
"r11",
"r12",
"r250",
"r257"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
"label": "Stock Repurchased During Period Value",
"negatedLabel": "Repurchases of common stock",
"terseLabel": "Stock repurchased during period, value"
}
}
},
"localname": "StockRepurchasedDuringPeriodValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityNarrativeDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r12",
"r16",
"r17",
"r87",
"r190",
"r191",
"r411"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"order": 10030.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
"label": "Stockholders Equity",
"periodEndLabel": "Balance at end of period",
"periodStartLabel": "Balance at beginning of period",
"totalLabel": "Total shareholders\u2019 equity"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccumulatedOtherComprehensiveLossNetOfTaxesDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Stockholders Equity [Abstract]",
"terseLabel": "Shareholders\u2019 equity:"
}
}
},
"localname": "StockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
"auth_ref": [
"r86",
"r257",
"r259"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
"label": "Stockholders Equity Note Disclosure [Text Block]",
"terseLabel": "Shareholders' Equity"
}
}
},
"localname": "StockholdersEquityNoteDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquity"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_TradingSecurities": {
"auth_ref": [
"r464"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
"order": 10030.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
"label": "Trading Securities",
"terseLabel": "Trading securities"
}
}
},
"localname": "TradingSecurities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
"auth_ref": [
"r258"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
"label": "Treasury Stock Acquired Average Cost Per Share",
"terseLabel": "Stock repurchased, average price paid per share (USD per share)"
}
}
},
"localname": "TreasuryStockAcquiredAverageCostPerShare",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureShareholdersEquityRepurchaseActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_TypeOfRestructuringDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Identification of the types of restructuring costs.",
"label": "Type Of Restructuring [Domain]",
"terseLabel": "Type of Restructuring"
}
}
},
"localname": "TypeOfRestructuringDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsLiabilitiesAssociatedWithRestructuringAndOtherCostsDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsScheduleOfRestructuringAndRelatedCostsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_UnbilledReceivablesCurrent": {
"auth_ref": [
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccountsReceivableAndUnbilledServicesNetDetails": {
"order": 10020.0,
"parentTag": "synh_ReceivablesNetCurrentAndContractWithCustomerAssetNetCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.",
"label": "Unbilled Receivables Current",
"terseLabel": "Accounts receivable unbilled"
}
}
},
"localname": "UnbilledReceivablesCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccountsReceivableAndUnbilledServicesNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_UnrecognizedTaxBenefits": {
"auth_ref": [
"r318",
"r326"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of unrecognized tax benefits.",
"label": "Unrecognized Tax Benefits",
"terseLabel": "Gross unrecognized tax benefits"
}
}
},
"localname": "UnrecognizedTaxBenefits",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
"auth_ref": [
"r326"
],
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
"label": "Unrecognized Tax Benefits Period Increase Decrease",
"terseLabel": "Increase in unrecognized tax benefit in foreign jurisdictions"
}
}
},
"localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
"auth_ref": [
"r327"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
"label": "Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations",
"terseLabel": "Decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations"
}
}
},
"localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_UnsecuredDebtMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
"label": "Unsecured Debt [Member]",
"terseLabel": "Unsecured Debt"
}
}
},
"localname": "UnsecuredDebtMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsScheduleOfDebtObligationsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ValuationAllowancesAndReservesBalance": {
"auth_ref": [
"r94",
"r98"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of valuation and qualifying accounts and reserves.",
"label": "Valuation Allowances And Reserves Balance",
"periodEndLabel": "Balance at the end of the period",
"periodStartLabel": "Balance at the beginning of the period"
}
}
},
"localname": "ValuationAllowancesAndReservesBalance",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsLiabilitiesAssociatedWithRestructuringAndOtherCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ValuationAllowancesAndReservesDeductions": {
"auth_ref": [
"r97"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
"label": "Valuation Allowances And Reserves Deductions",
"negatedLabel": "Payments"
}
}
},
"localname": "ValuationAllowancesAndReservesDeductions",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsLiabilitiesAssociatedWithRestructuringAndOtherCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ValuationAllowancesAndReservesDomain": {
"auth_ref": [
"r94",
"r95",
"r96",
"r97",
"r98"
],
"lang": {
"en-us": {
"role": {
"documentation": "Valuation and qualifying accounts and reserves.",
"label": "Valuation Allowances And Reserves [Domain]",
"terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves"
}
}
},
"localname": "ValuationAllowancesAndReservesDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsLiabilitiesAssociatedWithRestructuringAndOtherCostsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ValuationAllowancesAndReservesTypeAxis": {
"auth_ref": [
"r94",
"r95",
"r96",
"r97",
"r98"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by valuation and qualifying accounts and reserves.",
"label": "Valuation Allowances And Reserves Type [Axis]",
"terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type"
}
}
},
"localname": "ValuationAllowancesAndReservesTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureRestructuringAndOtherCostsLiabilitiesAssociatedWithRestructuringAndOtherCostsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_VariableRateAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of variable rate.",
"label": "Variable Rate [Axis]",
"terseLabel": "Variable Rate"
}
}
},
"localname": "VariableRateAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_VariableRateDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
"label": "Variable Rate [Domain]",
"terseLabel": "Variable Rate"
}
}
},
"localname": "VariableRateDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureLongTermDebtObligationsAccountsReceivableFinancingAgreementDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Weighted Average Number Diluted Shares Outstanding Adjustment [Abstract]",
"terseLabel": "Effect of dilutive securities:"
}
}
},
"localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"auth_ref": [
"r118",
"r128"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"lang": {
"en-us": {
"role": {
"documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
"label": "Weighted Average Number Of Diluted Shares Outstanding",
"terseLabel": "Diluted (in shares)",
"totalLabel": "Diluted weighted average common shares outstanding (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
"auth_ref": [
"r117",
"r128"
],
"calculation": {
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails": {
"order": 10010.0,
"parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
"label": "Weighted Average Number Of Shares Outstanding Basic",
"terseLabel": "Basic (in shares)",
"verboseLabel": "Basic weighted average common shares outstanding (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingBasic",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Weighted Average Number Of Shares Outstanding Diluted Disclosure Items [Abstract]",
"terseLabel": "Weighted average common shares outstanding:",
"verboseLabel": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.syneoshealth.com/20210331/taxonomy/role/DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
"http://www.syneoshealth.com/20210331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
],
"xbrltype": "stringItemType"
}
},
"unitCount": 8
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r100": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "http://asc.fasb.org/topic&trid=2122369"
},
"r101": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(4)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
},
"r111": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "28A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "55",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "52",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
},
"r134": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "260",
"URI": "http://asc.fasb.org/topic&trid=2144383"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
},
"r138": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r141": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
},
"r145": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "275",
"URI": "http://asc.fasb.org/topic&trid=2134479"
},
"r146": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(4))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(j)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "26",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "34",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "a",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "b",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "42",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
},
"r185": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "280",
"URI": "http://asc.fasb.org/topic&trid=2134510"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
},
"r188": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(4)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
},
"r195": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(3)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(4)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
},
"r2": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(7))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(8))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r210": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "((a)(1),(b))",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(2)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(1)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.17)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 5.P.3)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 5.P.4)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(b)(1))",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(d))",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r226": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "420",
"URI": "http://asc.fasb.org/topic&trid=2175745"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "440",
"URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "440",
"URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
},
"r229": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "440",
"URI": "http://asc.fasb.org/topic&trid=2144648"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
},
"r236": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
},
"r237": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "450",
"URI": "http://asc.fasb.org/topic&trid=2127136"
},
"r238": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "460",
"URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "460",
"URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(b),22(b))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r240": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
},
"r244": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "40",
"SubTopic": "50",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
},
"r245": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "40",
"SubTopic": "50",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
},
"r246": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "470",
"URI": "http://asc.fasb.org/topic&trid=2208564"
},
"r247": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(CFRR 211.02)",
"Topic": "480",
"URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19-26)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
},
"r251": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
},
"r255": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
},
"r256": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
},
"r257": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
},
"r258": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
},
"r259": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "505",
"URI": "http://asc.fasb.org/topic&trid=2208762"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
},
"r264": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
},
"r267": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "12A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL108322424-203045"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
},
"r272": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
},
"r275": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
},
"r278": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
},
"r279": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r280": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
},
"r281": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
},
"r282": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
},
"r283": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
},
"r285": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
},
"r286": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
},
"r287": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "606",
"URI": "http://asc.fasb.org/topic&trid=49130388"
},
"r288": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(i)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r289": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(ii)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.24)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r290": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(01)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r291": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r292": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(A)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r293": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(B)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r294": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(C)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r295": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(03)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r296": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(n)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r297": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
},
"r298": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(a)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
},
"r299": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(d)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.25)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r300": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(f)(3)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
},
"r301": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(a)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
},
"r302": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "80",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
},
"r303": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
},
"r304": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
},
"r305": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)(i)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r306": {
"Name": "Accounting Standards Codification",
"Paragraph": "2A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
},
"r307": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r308": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r309": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.28,29)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r310": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r311": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r312": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r313": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r314": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(g)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r315": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 14.F)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
},
"r316": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
},
"r317": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
},
"r318": {
"Name": "Accounting Standards Codification",
"Paragraph": "10B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
},
"r319": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r320": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
},
"r321": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
},
"r322": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
},
"r323": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
},
"r324": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
},
"r325": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
},
"r326": {
"Name": "Accounting Standards Codification",
"Paragraph": "15A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
},
"r327": {
"Name": "Accounting Standards Codification",
"Paragraph": "15A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(4)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
},
"r328": {
"Name": "Accounting Standards Codification",
"Paragraph": "15A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
},
"r329": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.3,4)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r330": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
},
"r331": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
},
"r332": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
},
"r333": {
"Name": "Accounting Standards Codification",
"Paragraph": "217",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
},
"r334": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740"
},
"r335": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740"
},
"r336": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
},
"r337": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 6.I.7)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
},
"r338": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.7)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
},
"r339": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.Fact.1)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.9)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r340": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.Fact.2)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
},
"r341": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.Fact.4)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
},
"r342": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.C)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
},
"r343": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
},
"r344": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "270",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
},
"r345": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
},
"r346": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "740",
"URI": "http://asc.fasb.org/topic&trid=2144680"
},
"r347": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "10",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e961-128460"
},
"r348": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
},
"r349": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
},
"r350": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
},
"r351": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
},
"r352": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "30",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
},
"r353": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "30",
"SubTopic": "30",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
},
"r354": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "30",
"SubTopic": "30",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
},
"r355": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
},
"r356": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
},
"r357": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(c)(1)",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
},
"r358": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(1)",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
},
"r359": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "805",
"URI": "http://asc.fasb.org/topic&trid=2303972"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
},
"r360": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
},
"r361": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
},
"r362": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r363": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r364": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(3)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r365": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c),(3)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r366": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
},
"r367": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
},
"r368": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
},
"r369": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
},
"r370": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
},
"r371": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
},
"r372": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)(ii)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
},
"r373": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
},
"r374": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
},
"r375": {
"Name": "Accounting Standards Codification",
"Paragraph": "4A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
},
"r376": {
"Name": "Accounting Standards Codification",
"Paragraph": "4A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
},
"r377": {
"Name": "Accounting Standards Codification",
"Paragraph": "4B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
},
"r378": {
"Name": "Accounting Standards Codification",
"Paragraph": "4B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
},
"r379": {
"Name": "Accounting Standards Codification",
"Paragraph": "4B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a),(b),(c)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
},
"r380": {
"Name": "Accounting Standards Codification",
"Paragraph": "4C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
},
"r381": {
"Name": "Accounting Standards Codification",
"Paragraph": "4D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
},
"r382": {
"Name": "Accounting Standards Codification",
"Paragraph": "4D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
},
"r383": {
"Name": "Accounting Standards Codification",
"Paragraph": "4E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
},
"r384": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
},
"r385": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
},
"r386": {
"Name": "Accounting Standards Codification",
"Paragraph": "182",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
},
"r387": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "25",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
},
"r388": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "815",
"URI": "http://asc.fasb.org/topic&trid=2229140"
},
"r389": {
"Name": "Accounting Standards Codification",
"Paragraph": "54B",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117332851&loc=SL7495116-110257"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
},
"r390": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r391": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r392": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r393": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(1)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r394": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(2)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r395": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r396": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r397": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r398": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(3)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r399": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
},
"r400": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r401": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
},
"r402": {
"Name": "Accounting Standards Codification",
"Paragraph": "6A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
},
"r403": {
"Name": "Accounting Standards Codification",
"Paragraph": "6A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
},
"r404": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
},
"r405": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
},
"r406": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
},
"r407": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
},
"r408": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
},
"r409": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
},
"r410": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
},
"r411": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
},
"r412": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
},
"r413": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
},
"r414": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
},
"r415": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30755-110894"
},
"r416": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
},
"r417": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
},
"r418": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
},
"r419": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
},
"r420": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r421": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r422": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r423": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r424": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
},
"r425": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
},
"r426": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
},
"r427": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
},
"r428": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
},
"r429": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
},
"r430": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28567-108399"
},
"r431": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
},
"r432": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "840",
"URI": "http://asc.fasb.org/extlink&oid=121569800&loc=d3e45023-112735"
},
"r433": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "840",
"URI": "http://asc.fasb.org/extlink&oid=121616839&loc=d3e45280-112737"
},
"r434": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
},
"r435": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
},
"r436": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r437": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r438": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r439": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "14A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
},
"r440": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r441": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
},
"r442": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
},
"r443": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
},
"r444": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "850",
"URI": "http://asc.fasb.org/topic&trid=2122745"
},
"r445": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "855",
"URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
},
"r446": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r447": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r448": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r449": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "17A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580"
},
"r450": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r451": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r452": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r453": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r454": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r455": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "910",
"URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
},
"r456": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
},
"r457": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "20",
"Topic": "940",
"URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
},
"r458": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(10)(1))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r459": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "17B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
},
"r460": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(13))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r461": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(16))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r462": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r463": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.17)",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r464": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.4)",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r465": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(15))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r466": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(22))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r467": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(26))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r468": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(27))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r469": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04.9)",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
},
"r470": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "235",
"Subparagraph": "(SX 210.9-05(b)(2))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
},
"r471": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "470",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
},
"r472": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(16))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r473": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r474": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(16))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r475": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r476": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r477": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r478": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(8))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r479": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.(a),19)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
},
"r480": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(18))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r481": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(22))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r482": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(23))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r483": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(8))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r484": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(9))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r485": {
"Name": "Accounting Standards Codification",
"Paragraph": "4H",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
},
"r486": {
"Name": "Accounting Standards Codification",
"Paragraph": "7A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(d)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
},
"r487": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(b)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
},
"r488": {
"Name": "Accounting Standards Codification",
"Paragraph": "29F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
},
"r489": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
},
"r490": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(b)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r491": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r492": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r493": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r494": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(1)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r495": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r496": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(ii)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r497": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(iii)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r498": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(iv)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r499": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(1)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(13))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
},
"r500": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r501": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "825",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
},
"r502": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07.1(c))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
},
"r503": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
},
"r504": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
},
"r505": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
},
"r506": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
},
"r507": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
},
"r508": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
},
"r509": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
},
"r510": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
},
"r511": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
},
"r512": {
"Name": "Accounting Standards Codification",
"Paragraph": "5D",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
},
"r513": {
"Name": "Accounting Standards Codification",
"Paragraph": "5D",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
},
"r514": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-15(Column A))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
},
"r515": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-15(Column B))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
},
"r516": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-15(Column C))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
},
"r517": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-15(Column D))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
},
"r518": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "310",
"Subparagraph": "(SX 210.12-29(Footnote 4))",
"Topic": "948",
"URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
},
"r519": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column B))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
},
"r520": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column C))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r521": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column D))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r522": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column E))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r523": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column F))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r524": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column G))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r525": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column H))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r526": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column I))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r527": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Footnote 2))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r528": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Footnote 4))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r529": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
},
"r530": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1"
},
"r531": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "308",
"Subsection": "a"
},
"r532": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1"
},
"r533": {
"Name": "Regulation 12B",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r534": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(210.5-03(11))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(1))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(10))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(20))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(24))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(25))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(14))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(5))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r62": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.1(e))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.2(a),(d))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.9)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(19))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
},
"r76": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
},
"r79": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r80": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
},
"r81": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(d))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(e)(1))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r89": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(k))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(22))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08.(e),(f))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08.(f))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08.(m)(1))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-04.(a))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-09(Column B))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-09(Column C(1)))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-09(Column C(2)))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-09(Column D))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-09(Column E))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-09(ColumnA))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
}
},
"version": "2.1"
} |
